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David A Harrison ,1 M Zia Sadique ,2 Richard D Grieve ,2
Julie Camsooksai ,3 Robert Darnell ,1 Anthony C Gordon ,4,5
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Background: Vasopressors are administered to critical care patients to avoid hypotension, which is
associated with myocardial injury, kidney injury and death. However, they work by causing vasoconstriction,
which may reduce blood flow and cause other adverse effects. A mean arterial pressure target typically
guides administration. An individual patient data meta-analysis (Lamontagne F, Day AG, Meade MO,
Cook DJ, Guyatt GH, Hylands M, et al. Pooled analysis of higher versus lower blood pressure targets
for vasopressor therapy septic and vasodilatory shock. Intensive Care Med 2018;44:12–21) suggested
that greater exposure, through higher mean arterial pressure targets, may increase risk of death in
older patients.
Objective: To estimate the clinical effectiveness and cost-effectiveness of reduced vasopressor
exposure through permissive hypotension (i.e. a lower mean arterial pressure target of 60–65 mmHg)
in older critically ill patients.
Design: A pragmatic, randomised clinical trial with integrated economic evaluation.
Setting: Sixty-five NHS adult general critical care units.
Participants: Critically ill patients aged ≥ 65 years receiving vasopressors for vasodilatory hypotension.
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Interventions: Intervention – permissive hypotension (i.e. a mean arterial pressure target of
60–65 mmHg). Control (usual care) – a mean arterial pressure target at the treating clinician’s
discretion.
Main outcome measures: The primary clinical outcome was 90-day all-cause mortality. The primary
cost-effectiveness outcome was 90-day incremental net monetary benefit. Secondary outcomes
included receipt and duration of advanced respiratory and renal support, mortality at critical care and
acute hospital discharge, and questionnaire assessment of cognitive decline and health-related quality
of life at 90 days and 1 year.
Results: Of 2600 patients randomised, 2463 (permissive hypotension, n = 1221; usual care, n = 1242)
were analysed for the primary clinical outcome. Permissive hypotension resulted in lower exposure to
vasopressors than usual care [mean duration 46.0 vs. 55.9 hours, difference –9.9 hours (95% confidence
interval –14.3 to –5.5 hours); total noradrenaline-equivalent dose 31.5 mg vs. 44.3 mg, difference
–12.8 mg (95% CI –18.0 mg to –17.6 mg)]. By 90 days, 500 (41.0%) patients in the permissive hypotension
group and 544 (43.8%) patients in the usual-care group had died (absolute risk difference –2.85%,
95% confidence interval –6.75% to 1.05%; p = 0.154). Adjustment for prespecified baseline variables
resulted in an odds ratio for 90-day mortality of 0.82 (95% confidence interval 0.68 to 0.98) favouring
permissive hypotension. There were no significant differences in prespecified secondary outcomes or
subgroups; however, patients with chronic hypertension showed a mortality difference favourable to
permissive hypotension. At 90 days, permissive hypotension showed similar costs to usual care.
However, with higher incremental life-years and quality-adjusted life-years in the permissive hypotension
group, the incremental net monetary benefit was positive, but with high statistical uncertainty (£378,
95% confidence interval −£1347 to £2103).
Limitations: The intervention was unblinded, with risk of bias minimised through central allocation
concealment and a primary outcome not subject to observer bias. The control group event rate was
higher than anticipated.
Conclusions: In critically ill patients aged ≥ 65 years receiving vasopressors for vasodilatory hypotension,
permissive hypotension did not significantly reduce 90-day mortality compared with usual care.
The absolute treatment effect on 90-day mortality, based on 95% confidence intervals, was between a
6.8-percentage reduction and a 1.1-percentage increase in mortality.
Future work: Future work should (1) update the individual patient data meta-analysis, (2) explore
approaches for evaluating heterogeneity of treatment effect and (3) explore 65 trial conduct, including
use of deferred consent, to inform future trials.
Trial registration: Current Controlled Trials ISRCTN10580502.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 14. See the NIHR Journals Library website for further project information.
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Low blood pressure is common in patients in intensive care. It is associated with a high risk of death.It can be treated with drugs called vasopressors. These drugs raise blood pressure, but also come
with risks and side effects. Usually, a blood pressure target is used to guide how much of the drugs to
give to patients.
Two previous clinical trials suggested that using a lower blood pressure target (and therefore giving
less of the drugs) might reduce the number of deaths among older patients. However, although these
results were promising, more research was needed to find out if they were correct.
The 65 trial was carried out to test if using a lower blood pressure target really did improve outcomes
for older patients. The trial also looked at whether or not it would provide value for money for the NHS.
A total of 2600 patients aged ≥ 65 years who had low blood pressure in intensive care joined the trial.
Half were randomly assigned to the new lower blood pressure target (less drugs). The other half were
assigned to usual care (control group). As we had hoped, patients in the low blood pressure target
group received less vasopressor drugs than the usual-care group.
After 90 days, 41% of patients in the new low blood pressure target group had died, compared with
44% in the usual-care group. Although fewer patients died in the low blood pressure target group,
the difference was small and may have occurred by chance. On average, the new target saved a small
amount of money for the NHS.
Although we could not prove that use of a lower blood pressure target saves lives for older patients
in intensive care, our trial suggests that it might. Receiving less vasopressor drugs appeared safe
for patients.
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Vasopressors are life-sustaining drugs that are administered to patients in critical care to avoid
hypotension, which is associated with myocardial injury, kidney injury and death. However, they work
by causing vasoconstriction, which may reduce blood flow and cause other secondary effects on
cardiac, metabolic, microbiome and immune function.
To guide vasopressor administration, doctors typically prescribe a mean arterial pressure target and
bedside nurses adjust the dose/rate of vasopressor infusions to achieve the target mean arterial
pressure. The 2012 Surviving Sepsis Campaign guidelines recommended maintaining a mean arterial
pressure of > 65 mmHg (Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al.
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock,
2012. Intensive Care Med 2013;39:165–228); however, the guidelines were based on low-quality
evidence and did not provide guidance for an upper limit. The guidelines also suggested a higher mean
arterial pressure target for older patients and those with chronic hypertension, recommendations
that were later removed in 2016. Studies suggest that, as the optimal mean arterial pressure target is
not well established, clinicians tend to err on the side of targeting higher mean arterial pressures,
potentially exposing patients to greater doses and durations of vasopressors than may be necessary.
An individual patient data meta-analysis of two randomised clinical trials that evaluated different mean
arterial pressure targets suggested that increased exposure to vasopressors, through targeting higher
mean arterial pressures, may be associated with a greater risk of death in older critically ill patients
(Lamontagne F, Day AG, Meade MO, Cook DJ, Guyatt GH, Hylands M, et al. Pooled analysis of higher
versus lower blood pressure targets for vasopressor therapy septic and vasodilatory shock. Intensive
Care Med 2018;44:12–21; Lamontagne F, Meade MO, Hébert PC, Asfar P, Lauzier F, Seely AJE, et al.
Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot
randomized controlled trial. Intensive Care Med 2016;42:542–50; and Asfar P, Meziani F, Hamel JF,
Grelon F, Megarbane B, Anguel N, et al. High versus low blood-pressure target in patients with septic
shock. N Engl J Med 2014;370:1583–93).
Aim and objective
Aim
The aim was to estimate the clinical effectiveness and cost-effectiveness of reduced vasopressor
exposure through permissive hypotension (i.e. a lower mean arterial pressure target of 60–65 mmHg)
in older critically ill patients.
Objective
The objective was to estimate the clinical effectiveness and cost-effectiveness of permissive
hypotension when compared with usual care.
Methods
Trial design and governance
The 65 trial was a pragmatic, multicentre, parallel-group, open-label, randomised clinical trial of
reduced exposure to vasopressors through permissive hypotension (i.e. a lower mean arterial pressure
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target of 60–65mmHg), with an integrated economic evaluation. The trial was nested in the Case Mix
Programme (i.e. the national clinical audit for adult critical care). The Health Research Authority
(London, UK) and the South Central – Oxford C Research Ethics Committee (Oxford, UK) approved
the trial. The National Institute for Health Research convened a majority independent Trial Steering
Committee and an independent Data Monitoring and Ethics Committee. The trial was sponsored by the
Intensive Care National Audit & Research Centre (London, UK) and co-ordinated by the Intensive Care
National Audit & Research Centre Clinical Trials Unit.
Participants: sites and patients
Based on Case Mix Programme data, a sample size of 2600 patients (i.e. 1300 patients per group)
was calculated to provide 90% power to detect as statistically significant (p < 0.05) a 6% absolute
risk reduction.
Across 65 NHS adult general critical care units (‘sites’), patients were screened and randomised if:
l they were aged ≥ 65 years
l they had vasodilatory hypotension (assessed by treating clinician)
l they had started an infusion (for at least 1 hour) of vasopressors within the prior 6 hours
(if noradrenaline, then a minimum infusion rate of 0.1 µg/kg/minute was required)
l they had adequate fluid resuscitation completed or ongoing
l vasopressors were expected to be continued for ≥ 6 further hours.
Owing to the emergency and time-sensitive nature of critical care and vasopressor administration,
the Research Ethics Committee granted an emergency waiver of consent and a research without prior
consent model was used (i.e. consent was sought after randomisation). Patients were randomised
(by telephone or internet) in a 1 : 1 ratio, using permuted blocks of variable length and stratified by
site to either the permissive hypotension (intervention) group or the usual-care (control) group.
Treatment groups
‘Permissive hypotension’ aimed to reduce exposure (i.e. dose and duration) to vasopressors through use
of a lower mean arterial pressure target range (60–65 mmHg) to guide vasopressor administration.
The choice of vasopressor was at the discretion of the treating clinician, with administration (aside
from the mean arterial pressure target) as per local practice and guidelines. The decision to discontinue
vasopressors depended on the patient’s ability to maintain the mean arterial pressure targeted by the
protocol without vasopressors. Clinical teams were actively reminded to consider discontinuing
vasopressors if patients were able to maintain mean arterial pressure values of at least 60 mmHg.
Patients randomised to the usual-care group received usual vasopressor exposure (including the mean
arterial pressure target) at the discretion of the treating clinician and as per local practice and guidelines.
Treating clinician(s) were aware of treatment allocations. All other usual care was provided at the
discretion of the treating clinical team, as per local practice.
Outcome measures
The primary clinical outcome was all-cause mortality at 90 days. The primary cost-effectiveness
outcome was incremental net monetary benefit at 90 days.
Secondary outcomes were mortality at discharge from critical care and acute hospital; duration of
survival to longest available follow-up; receipt and duration of advanced respiratory and renal support
during the critical care stay; days alive and free of advanced respiratory support and renal support to
28 days; duration of critical care and acute hospital stay; and questionnaire assessment of cognitive
decline (using the Informant Questionnaire on Cognitive Decline in the Elderly short version) and
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health-related quality of life (using the EuroQol-5 Dimensions, five-level version) at 90 days and 1 year.
Secondary economic outcomes included resource use, costs and incremental net monetary benefit at
1 year. Adverse events were monitored to critical care unit discharge.
Data sources
A secure, dedicated electronic case report form enabled trial data to be entered by local site research
teams. To maximise efficiency, trial data were linked to the Case Mix Programme (via the Intensive
Care National Audit & Research Centre) and national death registrations (via NHS Digital) for patient
characteristic, treatment and outcome data. Surviving patients were mailed questionnaires at 90 days
and 1 year, with telephone follow-up to non-responders.
Analysis principles
Analyses followed the intention-to-treat principle and tested for superiority, following a prespecified
published statistical analysis plan. A p-value of 0.05 was considered statistically significant. All tests
were two-sided, with no adjustment for multiple comparisons. Effect estimates were reported with
95% confidence intervals. Continuous variables were reported as means and standard deviations or
medians and interquartile ranges. Categorical variables were reported as counts and proportions.
Missing data were handled by multiple imputation.
Analysis methods
Fisher’s exact test compared between-group differences in the primary clinical outcome. The absolute
risk reduction was reported with 95% confidence intervals and without adjustment as the primary
effect estimate. Secondary and sensitivity analyses of the primary outcome were conducted, including
an analysis adjusted for baseline data using multilevel logistic regression with a random effect of site.
We also carried out prespecified subgroup analyses of the primary outcome testing interactions for
age, chronic hypertension, chronic heart failure, atherosclerotic disease, Intensive Care National Audit
& Research Centre risk of death score, Sepsis-3 category and vasopressors received at randomisation.
Likelihood ratio tests were used to compare models with and without the relevant interaction terms.
The cost-effectiveness analyses took an NHS and Personal Social Services perspective, as recommended
by the National Institute for Health and Care Excellence (London, UK), and reported quality-adjusted
life-years by combining survival data with EuroQol-5 Dimensions, five-level version, index scores that
used the valuation set for England. We estimated the corresponding incremental net monetary benefit
by valuing incremental quality-adjusted life-years at the National Institute for Health and Care Excellence
recommended threshold (£20,000) for a quality-adjusted life-year gain and subtracting incremental costs.
The main assumptions were subjected to extensive sensitivity analyses.
Results
Sites and patients
Across the 65 sites, 2930 potentially eligible patients were identified, of whom 2600 were randomised
between 3 July 2017 and 16 March 2019. Randomisation occurred 24 hours per day and 7 days per
week. Two patients were randomised twice, resulting in 2598 unique patients (permissive hypotension,
n= 1291; usual care, n= 1307). After accounting for refusals and withdrawals of consent, 2463 patients
were analysed for the primary outcome (permissive hypotension, n = 1221; usual care, n = 1242).
The randomised groups were well matched at baseline. In both groups, the mean age of patients was
75 years and just under half (46%) had chronic hypertension. Prior to randomisation, the mean arterial
pressure was 69.9 mmHg in the permissive hypotension group and 71.1 mmHg in the usual-care group.
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Clinical management
Vasopressor management diverged immediately post randomisation. During the first episode of
vasopressors, permissive hypotension resulted in a lower exposure to vasopressors than did usual care,
in terms of both mean duration (46.0 vs. 55.9 hours, mean difference −9.9 hours, 95% confidence
interval −14.3 to −5.5 hours) and mean total noradrenaline-equivalent dose (31.5 mg vs. 44.3 mg,
mean difference −12.8 mg, 95% confidence interval −18.0 mg to −7.6 mg).
Mean and peak mean arterial pressure values were lower in the permissive hypotension group. One or
more occurrence of non-adherence occurred in 153 (11.9%) patients and, overall, non-adherence
represented 6% of the total time receiving vasopressors in the permissive hypotension group.
Clinical effectiveness
Primary outcome
At 90 days, 500 (41.0%) patients in the permissive hypotension group and 544 (43.8%) patients in the
usual-care group had died (absolute risk difference –2.85%, 95% confidence interval –6.75% to 1.05%;
p = 0.154).When adjusted for prespecified baseline variables, the odds ratio for 90-day mortality was 0.82
(95% confidence interval 0.68 to 0.98), compared with an unadjusted odds ratio of 0.89 (95% confidence
interval 0.76 to 1.04). Secondary and sensitivity analyses did not significantly alter the primary result.
There was no evidence of heterogeneity of treatment effect according to prespecified subgroups;
however, differences by chronic hypertension status were observed. For patients with chronic hypertension,
90-day mortality was 38.2% in the permissive hypotension group and 44.3% in the usual-care group
(adjusted odds ratio 0.67, 95% confidence interval 0.51 to 0.88), compared with 43.3% and 43.4%,
respectively, in patients without chronic hypertension (adjusted odds ratio 0.97, 95% confidence
interval 0.76 to 1.24) (test of interaction p = 0.047, not adjusted for multiple testing).
Secondary outcomes
At acute hospital discharge, 484 (39.3%) patients in the permissive hypotension group and 519 (41.5%)
patients in the usual-care group had died (absolute risk difference –2.23%, 95% confidence interval
–6.09% to 1.63%). Mean days alive and free of renal support to day 28 was 17.4 (standard deviation
13.2) days and 16.7 (standard deviation 13.4) days for permissive hypotension and usual care,
respectively. Other secondary outcomes, including critical care unit and acute hospital length of stay,
were similar between the groups. Cognitive decline, assessed in survivors at 90 days and 1 year using
the Informant Questionnaire on Cognitive Decline in the Elderly, was also similar.
Cost-effectiveness
At 90 days, the average cost and mean EuroQol-5 Dimensions, five-level version, index scores were similar
between groups. After adjustment for baseline characteristics, the incremental life-years and quality-
adjusted life-years were higher in the permissive hypotension group, with the majority of points (95%) in
the quadrants on the cost-effectiveness plane where permissive hypotension had higher mean quality-
adjusted life-years. Hence, the incremental net monetary benefit for permissive hypotension compared with
usual care was positive, but with a wide confidence interval. At £20,000 per quality-adjusted life-year, the
incremental net monetary benefit was £378 (95% confidence interval −£1347 to £2103). The probability
that permissive hypotension is cost-effective is 70% at the £20,000 per quality-adjusted life-year threshold.
Conclusions
In patients aged ≥ 65 years who received vasopressors for vasodilatory hypotension, permissive
hypotension did not significantly reduce mortality at 90 days. The absolute treatment effect on 90-day
mortality, based on the 95% confidence intervals, was between a 6.8-percentage reduction and a
1.1-percentage increase in mortality at 90 days.
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Implications for health care
Our results suggest that reducing exposure to vasopressors through permissive hypotension is unlikely
to be harmful and may even be beneficial for older critically ill patients, in keeping with recent trends
in reducing the intensity of other critical care interventions and associated side effects.
Recommendations for research
Recommendation 1
The opportunity to pool our data with those of the two previous randomised clinical trials (Lamontagne F,
Meade MO, Hébert PC, Asfar P, Lauzier F, Seely AJE, et al. Higher versus lower blood pressure targets
for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. Intensive Care Med
2016;42:542–50; and Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N, et al. High versus
low blood-pressure target in patients with septic shock. N Engl J Med 2014;370:1583–93) will give
additional power for evaluating this group of patients, including other potentially important subgroups.
As this will include data from the UK, France and Canada, it will enhance generalisability and improve
knowledge on this important area for critical care worldwide.
Recommendation 2
Further research should study the efficient conduct of our trial, which used simple, straightforward
procedures and a research without prior consent model, to further understand the implications of
these procedures with the hope of producing guidance for future studies in the critical care setting.
Trial registration
This trial is registered as ISRCTN10580502.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 14.
See the NIHR Journals Library website for further project information.
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Vasopressors are life-sustaining drugs that are administered to patients in critical care to avoid
hypotension, which is associated with myocardial injury, kidney injury and death.1,2 They work by
causing vasoconstriction, which may reduce blood flow and cause other secondary effects on cardiac,
metabolic, microbiome and immune function.3 Balancing the risks of hypotension with the risks of
vasopressors is a daily challenge when managing patients in critical care units.
National clinical audit data indicate that close to half (44%) of all patients admitted to adult general
critical care units across England, Wales and Northern Ireland have hypotension and receive
vasopressors. It is estimated that 40–50% of these cases will represent vasodilatory hypotension.
This is similar in other health-care systems.4,5
To guide vasopressor administration, doctors typically prescribe a mean arterial pressure (MAP) target
and bedside nurses adjust the dose/rate of vasopressor infusions to achieve the target MAP. The 2012
Surviving Sepsis Campaign guidelines6 recommended maintaining a MAP of > 65 mmHg; however, the
guidelines were based on low-quality evidence and did not provide guidance for an upper limit. The
guidelines also suggested a higher MAP target for older patients and those with chronic hypertension,
recommendations that were later removed in 2016.7,8 Studies suggest that, as the optimal MAP target
is not well established, clinicians tend to err on the side of targeting higher MAPs, potentially exposing
patients to greater doses and durations of vasopressors than may be necessary.9,10
An individual patient data meta-analysis11 of two randomised clinical trials (RCTs) that evaluated
different MAP targets12,13 suggested that increased exposure to vasopressors, through targeting higher
MAPs, may be associated with a greater risk of death in older critically ill patients.11,14
The 65 trial tests the hypothesis that, in critically ill patients aged ≥ 65 years who receive vasopressors
for vasodilatory hypotension, reducing vasopressor exposure through permissive hypotension (i.e. a MAP
target of 60–65 mmHg) compared with usual vasopressor exposure reduces 90-day mortality and is
cost-effective. This follows similar strategies to minimise the intensity of other critical care interventions,
including oxygen therapy,15 enteral feeding,16 mechanical ventilation,17 blood transfusions,18 intravenous
fluids for patients after trauma19 and severe febrile illness in children.20
Efficient design
The 65 trial was funded through the National Institute for Health Research (NIHR) Health Technology
Assessment programme Efficient Study Designs call and designed in such a way to maximise efficiency
and minimise the additional workload that research can create for critical care unit teams. The trial
took a data-enabled approach, maximising the use of routinely collected and available data. The trial
was nested in an existing network of research-active critical care units participating in the Case Mix
Programme (CMP). The CMP (i.e. the national clinical audit for adult critical care in England, Wales and
Northern Ireland) is a source of high-quality, robust and representative data.21 The trial additionally
utilised national death registration data held by NHS Digital. Primary data collection was largely
limited to protocol adherence and patient safety data.
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The aim was to evaluate the clinical effectiveness and cost-effectiveness of reducing vasopressor
exposure through permissive hypotension (using a MAP target of 60–65 mmHg) in critically ill patients
aged ≥ 65 years with vasodilatory hypotension.
Objective
The objective was to estimate the clinical effectiveness and cost-effectiveness of reducing vasopressor
exposure through permissive hypotension when compared with usual care.
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
Chapter 2 Methods
Reproduced with permission from Richards-Belle et al.22
Design
The 65 trial was a pragmatic, multicentre, parallel-group, open-label RCT of reduced exposure to
vasopressors through permissive hypotension (i.e. a lower MAP target of 60–65 mmHg) in older
critically ill patients with vasodilatory hypotension, with an integrated economic evaluation.22
Setting
The trial was carried out in NHS adult general critical care units in England, Wales and Northern Ireland.
Sites
The trial aimed to recruit eligible patients from a representative sample of 65 NHS adult general
critical care units. Adult general critical care units were defined as intensive care units (ICUs) or
combined ICU and high-dependency units. Standalone high-dependency units and specialist critical
care units (e.g. cardiothoracic) were excluded.
Eligibility/requirements
Sites were considered for participation if they were active participants in the CMP and able to:
l identify two local joint-principal investigators (PIs) – one critical care consultant and one senior
critical care nurse – to lead the 65 trial locally
l identify a 65 trial research nurse who would be responsible for day-to-day local trial co-ordination
l incorporate the 65 trial into routine critical care clinical practice
l agree to randomise eligible patients and adhere to individual patient randomisation allocations
l agree to data collection requirements and to maintain a screening and enrolment log
l continue active participation in the CMP
l comply with all responsibilities as stated in the 65 trial Clinical Trial Site Agreement and all
requirements of the protocol
l comply with the UK Policy Framework for Health and Social Care Research23 and the International
Conference on Harmonisation guidelines on good clinical practice.24
Site identification, initiation and activation
A call for expressions of interest was sent via e-mail to all adult general critical care units actively
participating in the CMP by the Intensive Care National Audit & Research Centre (ICNARC;
London, UK) Clinical Trials Unit (CTU). Advertisements were also placed on ICNARC’s website
(URL: www.icnarc.org) and Twitter feed (URL: www.twitter.com; Twitter, Inc., San Francisco, CA, USA).
Site initiation visits were planned for each site, facilitated by the chief investigator (PRM), lead clinical
investigator (FL) and/or trial manager (ARB). During the visits, the following were covered: trial
background/rationale and procedures for screening and randomising patients, seeking informed
deferred consent/opinion, data collection and safety monitoring.
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Investigator site files (ISFs) containing all essential documents [e.g. trial protocol, standard operating
procedures (covering screening, randomisation, delivery of the interventions, consent procedures,
safety monitoring, etc.), relevant approvals, information sheets and consent forms] were provided.
Sites were activated and authorised to commence screening and recruitment once the following were
in place:
l a completed site initiation visit
l all relevant institutional approvals (e.g. local confirmation of capacity and capability)
l a 65 trial Clinical Trial Site Agreement signed by the local NHS trust/health board and the sponsor
(i.e. ICNARC)
l a signed delegation log had been submitted to the ICNARC CTU.
Once the ICNARC CTU confirmed that all necessary documentation was in place, a site activation
e-mail was issued to the joint PIs.
Patients
The full flow of eligible patients through the 65 trial is shown in Figure 1.
Eligibility
The target population was critically ill patients aged ≥ 65 years receiving vasopressors for vasodilatory
hypotension. Patients were eligible if they met all inclusion criteria and none of the exclusion criteria.
Inclusion criteria
l Patients were aged ≥ 65 years.
l Patients had vasodilatory hypotension (assessed by treating clinician).
l Patients had started an infusion (for at least 1 hour) of vasopressors within the prior 6 hours
(if noradrenaline, then a minimum infusion rate of 0.1 µg/kg/minute was required).
l Patients had adequate fluid resuscitation completed or ongoing.
l Vasopressors were expected to be continued for ≥ 6 further hours.
In the original approved protocol, patients were eligible if a decision to start vasopressors (at any dose)
had been made. The inclusion criteria were updated in December 2017 after routine central monitoring
of available trial data for 159 control group patients had identified a group of patients who received only
a relatively short duration (and often low doses) of vasopressors. The inclusion criteria were therefore
refined to specify that, at the time of randomisation, patients must have been on a vasopressor infusion
for at least 1 hour and if receiving noradrenaline then they must have been on an infusion of at least
0.1 µg/kg/minute.
Exclusion criteria
l Vasopressors being used solely as therapy for bleeding, acute ventricular failure (left or right) or
post-cardiopulmonary bypass vasoplegia.
l Ongoing treatment for brain injury or spinal cord injury.
l Death perceived as imminent.
l Previous enrolment to the 65 trial.
Screening
Potentially eligible patients admitted (or accepted for admission) to the participating adult general
critical care unit were screened against the eligibility criteria by local clinical/research teams.
METHODS
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Site research teams maintained a screening and enrolment log of patients aged ≥ 65 years with
vasodilatory hypotension and who received vasopressors. The log detailed randomised patients,
reasons for exclusion and non-enrolment.
Randomisation
Patients were randomised in a 1 : 1 ratio to either the permissive hypotension group or to the usual-
care group, using a dedicated 24 hours per day, 7 days per week, telephone or web-based randomisation
service hosted by Sealed Envelope Ltd (URL: www.sealedenvelope.com/, London, UK). Allocation was
concealed, used randomised permuted blocks of variable lengths (of 4, 6 and 8) and stratified by
recruiting site. As the trial was large, the risk of chance imbalance in prognostic factors was low and the
need to randomise patients during a very short time frame mandated that the randomisation process
was as simple as possible. For these reasons, we elected not to stratify the randomisation process on
any baseline covariates.
24/7 screening of adults admitted to critical care
Patient meets all inclusion criteria:
• age ≥ 65 years
• vasodilatory hypotension
• started vasopressor infusion within prior 6 hours
    (if noradrenaline, then a minimum infusion rate of 0.1 μg/kg/minute)
• adequate fluid resuscitation
• vasopressors expected to continue for ≥ 6 hours
Randomised via dedicated 24/7 telephone randomisation service
(stratified by site) using approved deferred consent procedure
Consent to continued data collection and follow-up obtained
when patient regains mental capacity
Intervention group
Permissive hypotension –
a more conservative MAP target range
(60–65 mmHg) to guide titration
of vasopressors in order to
minimise dose and duration
Control group
Usual use of vasopressors
within usual clinical care
90 days post randomisation
All other care at the discretion of treating clinicians
Data linkage to national death registration for longer term follow-up
1 year post  randomisation
• Assessment of mortality (primary outcome)
• Patient questionnaire follow-up (survivors)
• Patient questionnaire follow-up (survivors)
FIGURE 1 Patient flow through the 65 trial. Reproduced with permission from Richards-Belle et al.22
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Treatment groups
Permissive hypotension (mean arterial pressure target 60–65 mmHg)
‘Permissive hypotension’ aimed to reduce exposure (i.e. dose and duration) to vasopressors through use
of a lower MAP target range (i.e. 60–65 mmHg) to guide vasopressor administration.
The choice of vasopressor was at the discretion of the treating clinician, with administration (aside from
the MAP target) as per local practice and guidelines. The following were considered as vasopressors:
noradrenaline, vasopressin, terlipressin, phenylephrine, adrenaline, dopamine and metaraminol.
The decision to discontinue vasopressors depended on the patients’ ability to maintain the MAP target
stipulated by the protocol without vasopressors. Clinical teams were actively reminded to consider
discontinuing vasopressor if the patient was able to maintain a MAP value of at least 60 mmHg.
The MAP target applied to any point during the critical care unit admission that the patient was deemed
to require vasopressors.
If a patient developed an exclusion criterion (see Exclusion criteria) after randomisation, it was at the
discretion of the treating clinical team whether or not the MAP target continued, with patient safety
guiding this decision.
Usual care
Patients randomised to the usual-care group received usual vasopressor exposure (including the MAP
target) at the discretion of the treating clinician and as per local practice and guidelines.
Treating clinician(s) were aware of the treatment allocation. All other usual care was provided at the
discretion of the treating clinical team and as per local practice.
Co-interventions
As per standard care of patients receiving vasopressors, central venous catheters (to avoid extravasation)
and arterial catheters (for close MAP monitoring) would usually be in place. The use of pure inotropes
{i.e. dobutamine, milrinone or levosimendan [Leximda, Orion Pharma (UK) Ltd]} fluids and corticosteroids
[e.g. hydrocortisone, methylprednisolone (Solu-Medrone, Pfizer Ltd), dexamethasone, prednisone/
prednisolone] was recorded, but left to the discretion of the treating team.
Consent procedures
Patients in critical care requiring vasopressors often need this treatment started as a life-saving
measure during an emergency, time-sensitive situation. The majority of patients lack mental capacity
because of their medical condition and the effects of concomitant treatments administered as part of
standard care (e.g. mechanical ventilation, sedative and analgesic drugs). Any delay in commencing
treatment could be detrimental to the patient and to the scientific validity of the trial. This, alongside
the potential distress of the emergency situation, rendered attempts to obtain either prospective
informed consent from the patient or the opinion of their personal consultee (i.e. relative or close
friend) prior to starting the trial treatment inappropriate.
Considering these reasons, eligible patients were enrolled and randomised to receive the allocated
treatment immediately. This method is known as ‘deferred consent’ or ‘research without prior consent’
and was covered by an emergency waiver of consent under the Mental Capacity Act25 and approved by
the South Central – Oxford C Research Ethics Committee (REC) (reference 17/SC/0142).
In the situation where a patient was deemed by the treating clinical team to have full mental capacity
and was able to provide prospective informed consent at the point of randomisation, they were
approached prior to randomisation for verbal consent. If providing verbal consent, they were then
followed up for full written informed consent, in line with the procedures outlined below.
METHODS
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Patient informed deferred consent
Following randomisation, patients were approached by an authorised, trained member of the site
research team when deemed to have full mental capacity to provide informed deferred consent.
A patient information sheet (PIS) (see Report Supplementary Material 1), providing information on the
aim of the trial, what participation would mean for the patient, confidentiality and data security, and
the future availability of the trial results, was provided to the patient. Patients were given time to read
the PIS and to ask any questions they had prior to confirming their consent decision. If in agreement,
a consent form (see Report Supplementary Material 2) was then provided, indicating that the information,
given orally and in writing, had been read and understood, and that participation was voluntary and
could be withdrawn at any time without consequence. The consent form covered options for continuing
participation, access to the medical records for ongoing data collection, questionnaire follow-up (i.e. at
90 days and 1 year) and the sharing of anonymised data.
After verifying that the PIS and consent form were understood, the trained member of the site
research team invited the patient to sign the consent form. A copy was given to the patient, a copy
placed in the patient’s medical records and the original kept in the local ISF. If the patient was unable
to physically sign the consent form (e.g. because of weakness or reduced dexterity), an independent
witness signed on their behalf and in their presence.
The patient’s general practitioner (GP) was then sent a letter by the site research team to inform them
of their patient’s participation in the trial (provided consent had been given for this).
Personal consultee opinion
For the reasons outlined in Consent procedures, it was usually not possible to involve patients in the
consent process early on. In the interim, once notified of the randomisation of a patient into the
65 trial, an authorised and trained member of the site research team approached the patient’s personal
consultee (i.e. relative or close friend) as soon as appropriate and practicably possible to discuss the
trial and to seek their opinion as to the patient’s likely wishes and feelings regarding participation.
Ideally, this approach would take place within 24–48 hours of randomisation, once the patient’s medical
situation was no longer considered an emergency (but the specific timing would vary according to each
patient’s clinical scenario).
The personal consultee was provided with a personal consultee information sheet (see Report Supplementary
Material 3), which contained all the information provided on the PIS, supplemented by information
about why the personal consultee was being approached at this stage. A personal consultee opinion
form (see Report Supplementary Material 4) was provided, which indicated that the information, given
orally and in writing, had been read and understood, the patient’s participation was voluntary and could
be withdrawn at any time without consequence, and that, in the personal consultee’s opinion, the patient
would not object to taking part.
Personal consultees were given time to read the personal consultee information sheet and were
invited to ask any questions they had about the patient’s participation in the 65 trial. After verifying
that the personal consultee information sheet and opinion form were understood, the trained member
of the site research team then invited the personal consultee to sign the personal consultee opinion
form. If a personal consultee advised that, in their opinion, the patient would not choose to participate,
then the trial treatment was stopped (if ongoing) and the personal consultee was asked if, in their
opinion, the patient would be willing to continue with ongoing data collection and/or to be followed up
at 90 days and 1 year.
On patient recovery, patients were approached directly for informed deferred consent (see Patient
informed deferred consent). The patient’s decision was final and superseded that of the personal
consultee when there was disagreement.
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7
Nominated consultee opinion
In the case of a patient who had died, a nominated consultee was appointed. The nominated consultee
could include an independent mental capacity advocate appointed by the NHS trust or an independent
doctor (i.e. not associated with the conduct of the trial). The opinion of the nominated consultee was
sought in the same manner as for the personal consultee.
A nominated consultee was also approached if no personal consultee was available or if one was
available but did not want to be consulted. On patient recovery, the patient was approached directly
for informed deferred consent (see Patient informed deferred consent). The patient’s decision was final
and superseded that of the nominated consultee when there was disagreement.
Discharge prior to consent/opinion being sought
If a patient was discharged from hospital with mental capacity prior to consent/opinion being
confirmed, the most appropriate member of the site research team followed up the patient by
telephone and post to obtain informed consent. If there was no response 4 weeks after contacting the
patient by post for a second time, the participant’s data were included in the trial unless the patient
notified the site research team otherwise.
If the patient was discharged without mental capacity, then the opinion of the personal consultee was
sought in line with the above process (i.e. telephone call then postal approach).
If the participant was transferred to another hospital participating in the trial before the consent
procedures were complete, then the local site research team contacted the site research team at the
receiving hospital to hand over the consenting procedures.
Refusal or withdrawals of consent/opinion
If patient-informed deferred consent (or consultee opinion) was refused or withdrawn, this decision
was respected and abided by, and no further contact made. All data up to the point of this decision
were retained in the trial records, unless the patient or consultee requested otherwise.
Safety monitoring
All patients eligible for the 65 trial were critically ill and, because of the complexity of their condition,
at increased risk of experiencing adverse events and serious adverse events (SAEs).26 In the 65 trial,
the labelling of a SAE was limited to serious events that might reasonably occur as a consequence of
either sustaining lower MAP values and/or higher doses of vasopressors required to maintain higher
MAP values. In addition to reporting any unexpected and possibly related SAEs, research teams were
asked to screen for, and record occurrences of, the following events (up to critical care unit discharge):
l supraventricular cardiac arrhythmia




l severe acute renal failure.
If occurring, each event was assessed for its severity, using the scale below:
l ‘None’ – no event or complication.
l ‘Mild’ – complications result in only temporary harm and do not require clinical treatment.
l ‘Moderate’ – complications require clinical treatment, but do not result in significant prolongation of
hospital stay. Does not usually result in permanent harm and, where this does occur, the harm does
not cause functional limitations to the patient.
METHODS
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l ‘Severe’ – complications require clinical treatment and result in significant prolongation of hospital
stay and/or permanent functional limitation.
l ‘Life-threatening’ – complications may lead to death.
l ‘Fatal’ – patient died as a direct result of the complication/adverse events.
A reportable event with the severity assessed as ‘severe’, ‘life-threatening’ or ‘fatal’ was considered a
SAE in the 65 trial and this was reported on the 65 trial SAE reporting form. On receipt, a member of
the ICNARC CTU trial team reviewed the form for completeness and internal consistency, which was
then followed by review by a clinical member of the 65 Trial Management Group (TMG) to evaluate
whether or not the event qualified for expedited reporting to the REC. If the event was judged to be
unexpected and potentially related to the trial intervention(s), the ICNARC CTU trial team submitted a
report to the REC within 15 calendar days.
Questionnaire follow-up
Health-related quality of life (HRQoL) [assessed using the EuroQol-5 Dimensions, five-level version
(EQ-5D-5L) questionnaire],27 cognitive decline [assessed using the Informant Questionnaire on
Cognitive Decline in the Elderly (IQCODE) short form]28 and health service and resource use were
collected via self-report follow-up questionnaires administered to surviving patients at 90 days and
1-year post randomisation. Follow-up for patient-reported 1-year outcomes was truncated and
completed when the last patient reached 90 days.
Allowing time for administrative procedures, the questionnaire follow-up process started at 82 days
post randomisation for the 90-day follow-up time point and at 358 days post randomisation for the
1-year follow-up time point. Patients who had died since leaving hospital were logged and the follow-up
process ended. Questionnaire packs were sent to participants by post and included a self-addressed
stamped envelope and pen for ease of return. Participants could indicate if they no longer wished to
complete the questionnaire.
Non-responders were telephoned 3 weeks later by a trained member of the 65 trial team from the
ICNARC CTU to check whether or not they had received the questionnaire and were given the
option to complete the questionnaire over the telephone or to receive another copy, either by post
or by e-mail.
For patients identified as current hospital inpatients, or residents in a care home or rehabilitation
centre, the relevant institution was contacted to establish the most appropriate way to proceed with
follow-up. If possible, staff members at the relevant institution assisted the patient with completion
and return to the ICNARC CTU.
Outcomes
Primary clinical outcome: 90-day mortality
The primary clinical outcome was 90-day mortality, defined as death due to any cause within 90 days
following the date of randomisation.
Secondary clinical outcomes
Mortality at discharge from the critical care unit and acute hospital
Mortality at discharge from the critical care unit was defined as death due to any cause before
discharge to any location providing a level of care less than level 2 (i.e. high-dependency care).
Mortality at discharge from acute hospital was defined as death due to any cause before discharge
from acute hospital. Patients transferred from the original acute hospital to another acute hospital
were followed up until they left the acute hospital.
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Duration of survival to longest available follow-up
Duration of survival was calculated as the duration (in days) from the date of randomisation to the
date of death. Patients were censored at the last date on which they were known to be alive.
Duration of advanced respiratory and renal support during the critical care unit stay
Advanced respiratory support and renal support were defined in accordance with the UK Department
of Health and Social Care’s Critical Care Minimum Data Set.29 Advanced respiratory support was defined
as receiving one or more of the following: invasive mechanical ventilatory support applied via a
translaryngeal tube or via a tracheostomy; bilevel positive airway pressure applied via a translaryngeal
tracheal tube or via a tracheostomy; continuous positive airway pressure via a translaryngeal tracheal
tube; or extracorporeal respiratory support. Note that mask/hood continuous positive airway pressure,
mask/hood bilevel positive airway pressure and high-flow nasal cannula were not considered advanced
respiratory support. Renal support was defined as receiving either acute renal replacement therapy
(e.g. haemodialysis, haemofiltration) or renal replacement therapy for chronic renal failure.
The duration of organ support was defined as the number of calendar days (00.00 to 23.59) on which
the organ support was received at any time. Any days outside the critical care unit were assumed to be
free of organ support.
Days alive and free of advanced respiratory and renal support within first 28 days
For patients surviving to 28 days following randomisation, the number of days alive and free of
advanced respiratory and renal support to day 28 was defined as the number of calendar days (00.00
to 23.59) on which neither advanced respiratory support nor renal support was received at any time.
Patients dying between randomisation and day 28 were assigned a value of zero.
Duration of critical care unit and acute hospital stay
Duration of critical care unit stay was calculated as the sum of the duration (in days) from the date
and time of randomisation to the date and time of first discharge from, or death in, the critical care
unit plus the duration of any subsequent admissions to the critical care unit within the same acute
hospital stay. Duration of acute hospital stay was calculated as the duration (in days) from the date of
randomisation to the date of discharge from, or death in, acute hospital.
Cognitive decline at 90 days and 1 year
Cognitive decline was assessed using the IQCODE short version,28 with the total score calculated as
the mean of the scores (from 1 to 5) on 16 items.
Primary economic outcome: incremental net monetary benefit at 90 days
The incremental net monetary benefit (INMB) of permissive hypotension compared with usual care
at 90 days was calculated by multiplying the mean gain or loss in quality-adjusted life-years (QALYs)
by the National Institute for Health and Care Excellence (NICE)-recommended threshold in the UK
(of £20,000) and subtracting the incremental cost.30,31
Secondary economic outcomes
Health-related quality of life at 90 days and 1 year
Health-related quality of life at 90 days and 1 year was measured using the EQ-5D-5L.27 The EQ-5D-5L
requires patients to describe their health on five dimensions: (1) mobility, (2) self-care, (3) usual activities,
(4) pain/discomfort and (5) anxiety/depression. The mean [standard deviation (SD)] was reported among
survivors at the relevant time point. EQ-5D-5L responses were used to report each patient’s described
health, which was then valued using the EQ-5D-5L value set for England 201832 according to health
state preferences from the general population to calculate EQ-5D-5L utility scores, anchored on a scale
from 0 (death) to 1 (perfect health).
METHODS
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Life-years and quality-adjusted life-years at 90 days and 1 year
The 65 trial data were linked with national death registrations held by NHS Digital. Information on
the date and time of deaths was used to calculate the survival time and life-years up to 90 days and
up to 1 year for each randomised patient. QALYs at 90 days were calculated by valuing each patient’s
survival time by their HRQoL at 90 days, according to the ‘area under the curve’ approach.33 For
survivors at 90 days, QALYs were calculated using the 90-day EQ-5D-5L scores, assuming an EQ-5D-5L
score of zero at randomisation and a linear interpolation between randomisation and 90 days. For
decedents between randomisation and 90 days, a zero QALY gain was assumed. The same approach was
taken to calculate the QALYs at 1 year.
Resource use and costs at 90 days and 1 year
Overview
Resource use categories considered were chosen a priori and according to those where differences
between the treatment groups were deemed likely to drive incremental costs. The categories were
resource use associated with the trial interventions, hospital admissions (index admission and
readmissions) and visits to outpatients and community health-care services. Vasopressor use (duration
and infusion rate) was judged as the key element of the trial interventions. Total costs at 90 days were
calculated by combining resource use data with unit costs at 2017/18 prices (GBP).
Intervention
The costs of vasopressors associated with delivering the trial interventions for both treatment groups
(i.e. permissive hypotension and usual care) were included. Detailed patient-level data on the volume
of vasopressor use were collected in the case report form (CRF). The costing of vasopressors was
informed by expert clinical opinion and based on standard dose/units of vasopressors (i.e. noradrenaline,
adrenaline, dopamine, phenylephrine, vasopressin, metaraminol, terlipressin) that are routinely used in
critical care units.
Hospital stay
The use of hospital resources from the index hospital admission (i.e. the hospital stay following
randomisation) and any readmission(s) to hospital was extracted from the CRF and CMP database.21
For each patient, location and duration of the index hospital admission (including time spent in critical
care and on general medical wards) were recorded up to 90 days. Length of stay in critical care was
calculated as total duration (in days), including fractions of days, from the date and time of randomisation
for the critical care unit stay during which the patient was randomised until the time of discharge from, or
death in, critical care. Within the index admission, the total duration of critical care stay included all time
spent in critical care between randomisation and discharge from acute hospital (including any transfers
to critical care units in other hospitals). Data on the number of organs supported on each day of critical
care were extracted from the CMP database and each critical care episode then assigned a Healthcare
Resource Group (HRG), applying a standard HRG grouper algorithm.29 For the index admission, total
length of stay was calculated as the total duration (in days) from the date of randomisation to the date
of ultimate discharge from, or death in, hospital.
A hospital readmission was defined as a further hospital admission after ultimate acute hospital discharge
from the index admission. Readmission data were collected from two sources: (1) the CMP database21 and
(2) health services questionnaires administered to patients surviving to 90 days. The former provided
information on duration of critical care unit stay and total hospital stay, including subsequent transfer to
other care areas (e.g. general medical wards) within the same hospital and to other hospitals. The latter
provided information on readmissions that did not include a further stay in critical care.
The resource use items included the total number of hospital outpatient visits and community service
use following discharge from the index admission but before 90 days post randomisation. Visits to
outpatient and community health-care services [e.g. GP visits, nurses (i.e. from the GP clinic, hospital
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or a psychiatric nurse), health visitor, occupational therapist, speech and language therapist, counsellor,
physiotherapist, psychiatrist and psychologist] were collected via the health service questionnaire.
Resource use items included usage for reasons both related and unrelated to the initial critical care
admission in which the patient was randomised.
Unit costs
The unit costs required for valuing the resource use data were taken from national unit cost databases
(Table 1). Vasopressor unit costs were taken from British National Formulary.34 The costs per critical care
bed-day by HRG and general medical bed-day were taken from the Payment by Results database.35
Unit costs for hospital outpatient visits and community service use were obtained from Unit Costs of
Health and Social Care.36 All unit costs were reported in 2017–18 prices.
Data collection and management
Case report forms/electronic case report forms
The data set was restricted to those fields required to confirm eligibility, to describe the patient population,
to describe and monitor protocol adherence, to assess primary and secondary outcomes and to enable
linkage to the CMP, NHS Digital and patient follow-up (Table 2).
A dedicated, secure electronic CRF was developed to enable site research staff to enter trial data.
Access to the trial database was restricted to authorised site research staff recorded on the local
delegation log and centrally approved by the data manager (NH or MS). Each individual was assigned
a unique username and had access to data only for patients recruited at their site.
Data management
To ensure completeness and accuracy, and to enable effective trial monitoring, data entered by
authorised site research staff into the electronic CRF were regularly checked and validated by the data
manager. This was carried out on an ongoing basis so that any issues could be identified by the trial
team in a timely manner. The electronic CRF had built-in functionality to prevent erroneous data from
being entered and checks for unusual and missing data. Other data queries were programmed using
either Structured Query Language or Stata® coding (StataCorp LP, College Station, TX, USA) and fed
back to site research teams via e-mail.
Data received from completed follow-up questionnaires were entered into a secure database at the
ICNARC CTU, following a standard operating procedure. Identifiable data (where present) were
removed and anonymised at the point of entry. Queries relating to the entry of follow-up questionnaires
were reviewed by the trial manager (ARB) and data manager (NH or MS), with disagreement reviewed
by a third member of the team, either the chief investigator (PRM) or health economist (ZS). To ensure
accuracy, 10% of questionnaires entered by each data entry personnel were cross-checked by a second
member of the ICNARC CTU team. In addition, all questionnaires with any missing EQ-5D-5L values
or three or more missing IQCODE item responses were checked and verified. Any errors found were
logged and corrected on the database.
Data linkage: Case Mix Programme and NHS Digital
65 trial data were linked to the CMP database by the trial statistician (KT) and, following the signing of
a data-sharing agreement, to national death registrations in the Medical Research Information Service
Database Administration Service, held by NHS Digital.
METHODS
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TABLE 1 Unit costs
Item Unit cost (£) Source
Vasopressor
Noradrenaline (4 mg) 5.8 BNF34
Dopamine (200 mg) 2 BNF34
Phenylephrine (10 mg) 5 BNF34
Terlipressin (1 mg) 17.9 BNF34
Adrenaline (1 mg) 0.6 BNF34
Vasopressin (1unit) 85 BNF34
Metaraminol (20 mg) 8.8 BNF34
Hospital costs (bed-day)
Critical care bed-day: zero organs supported 838 NHS reference costs35
Critical care bed-day: one organ supported 1136 NHS reference costs35
Critical care bed-day: two organs supported 1524 NHS reference costs35
Critical care bed-day: three organs supported 1710 NHS reference costs35
Critical care bed-day: four organs supported 1893 NHS reference costs35
Critical care bed-day: five organs supported 2038 NHS reference costs35
Critical care bed-day: six or more organs supported 2075 NHS reference costs35
General medical bed-day 337 NHS reference costs35
Outpatient and community health services
Hospital outpatient 134 PSSRU36
GP general practice visit (per visit) 37 PSSRU36
GP home visit (per visit) 86 PSSRU36
GP nurse visita 11 PSSRU36
GP nurse home visita 19 PSSRU36
Hospital nursea 9 PSSRU36
Health visitora 7 PSSRU36
Health visitor home visita 12 PSSRU36
Occupational therapista 9 PSSRU36
Physiotherapista 9 PSSRU36
Psychiatrista 27 PSSRU36
Psychiatric nursea 9 PSSRU36
Psychologista 14 PSSRU36
Counsellora 9 PSSRU36
Speech and language therapista 9 PSSRU36
BNF, British National Formulary; PSSRU, Personal Social Services Research Unit.
a Fifteen minutes of consultation time.
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Governance, management and oversight
Health Research Authority and research ethics application
An application for approval by the Health Research Authority (London, UK) and ethics opinion from
the South Central – Oxford C REC (Oxford, UK) was submitted on 7 March 2017. Following a meeting
of the REC on 31 March 2017, Health Research Authority approval and favourable ethics opinion were
both confirmed on 24 April 2017 (Integrated Research Application System number 215503 and REC
reference 17/SC/0142).
Substantial amendments
Following initial favourable ethics opinion, two substantial amendments were submitted, both of which
received favourable ethics opinion from the South Central – Oxford C REC. These were are follows:
1. To refine the inclusion criteria by specifying that participants must (a) have already commenced on
a vasopressor infusion prior to randomisation (for at least 1 hour) and (b) if receiving noradrenaline
(the most commonly used vasopressor), currently be receiving a dose of at least 0.1 µg/kg/minute
(see Inclusion criteria for further details). In addition, to meet NHS Digital consent materials
requirements, information sheets and consent/opinion forms were amended to include greater
detail on data processing.
2. To revise the trial power calculation following a recommendation by the Trial Steering Committee
(TSC) (see Final power calculation).
Local governance
Confirmation of capacity and capability was obtained from each participating NHS trust/health board
prior to commencement of recruitment. In addition, a clinical trial site agreement, based on the model
agreement for non-commercial research in the NHS, was signed by each participating NHS trust/health
board and the sponsor (i.e. ICNARC).

















Co-interventions data ✓ ✓










a 1-year questionnaire follow-up was curtailed and ended once the last patient completed their 90-day questionnaire.
Reproduced with permission from Richards-Belle et al.22
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Trial registration
To ensure transparency, the 65 trial was prospectively registered with the ISRCTN registry on
10 April 2017, with registration confirmed the following day (reference ISRCTN10580502).
Patient and public involvement
Two patient and public involvement (PPI) representatives (CW and DH) were trial co-investigators
and members of the TMG, and both were involved in the development and management of the trial
through to completion and dissemination. In addition, independent PPI representation was sought for
membership of the TSC.
Monitoring
The monitoring plan followed a risk-based strategy and was guided by recruitment and protocol
adherence data, with a view to visiting ≈ 25% of sites. On-site routine monitoring visits were carried
out at a total of 18 (28%) sites. At these visits, barriers to or difficulties in delivering the trial were
discussed and trial data/materials were reviewed. The latter included the ISF being checked for
completeness, patient consent (or consultee opinion) forms were checked for all patients randomised at
the time of the visit and source data verification was conducted on a random sample of patient CRFs.
After the visit, a report was provided by the trial monitor to the site PIs, which summarised findings
and actions required following the visit. The site PIs were responsible for resolving outstanding actions
and reporting back to the ICNARC CTU. Follow-up teleconferences were arranged to resolve residual
issues, if required.
Trial Management Group
The TMG was responsible for management of the trial and was led by the chief investigator (PRM) and
lead clinical investigator (FL), both of whom took overall responsibility for trial delivery and oversaw
progress against timelines and milestones. The TMG also comprised methodological, clinical and PPI
co-investigators and members of the ICNARC CTU trial team, and met regularly throughout the trial
period. The trial manager (ARB) was responsible for day-to-day management of the trial, with support
from the research assistant (RD), data manager (NH or MS) and trial statistician (KT).
Trial Steering Committee
The NIHR convened an independently chaired and majority (≥ 75%) independent TSC to provide
overall supervision of the trial on behalf of the funder and sponsor. The TSC was independently
chaired by Professor Tim Walsh (University of Edinburgh, Edinburgh, UK) and included experienced
clinicians, methodologists and a PPI representative.
Data Monitoring and Ethics Committee
The NIHR convened an independent Data Monitoring and Ethics Committee (DMEC), chaired by
Professor John Norrie (University of Edinburgh), to monitor recruitment, protocol adherence and
patient safety. The DMEC included experienced methodologists and clinicians.
Sponsorship
The 65 trial was sponsored by ICNARC and managed by the ICNARC CTU.
Network support
The 65 trial was adopted onto the NIHR central portfolio management system on 17 March 2017
(CPMS ID 34223) and supported by the NIHR Clinical Research Network (CRN) (division six).
CRN-supported research nurses were in place across most participating sites. The NIHR CRN Critical
Care Specialty Group monitored progress and presentations were held at local CRN meetings to maintain
awareness. In addition, the UK Critical Care Research Group supported the trial.
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All analyses adhered to the intention-to-treat principle. Patients were analysed according to the initial
treatment assignment, irrespective of whether or not the allocated treatment was received. All
patients for whom the primary outcome was known were included in the primary analysis, regardless
of protocol adherence. All statistical tests were performed for superiority and were two sided with
significance set at p < 0.05. Effect estimates are reported with 95% confidence intervals (CIs). There
was no adjustment for multiple testing. The results of subgroup analyses were interpreted, taking into
account accepted criteria for credible subgroup effects.37,38
Power calculations
Original power calculation
In the original approved protocol, the sample size was calculated as follows: assuming 90-day mortality
of 35% in the usual-care group (based on CMP data for patients aged ≥ 65 years admitted to critical
care and receiving advanced cardiovascular support), a sample size of 1402 patients provided 90% power
to detect as statistically significant (p < 0.05) an 8% absolute risk reduction to 27%. Allowing for
2.5% withdrawal/loss to follow-up, we aimed to recruit a total of 1440 patients.
Final power calculation
In a substantial amendment to the protocol (from version 2.0 to 3.0), the expected absolute risk
reduction was changed from 8% to 6% (i.e. an expected 90-day mortality of 29% in the intervention
group, with all other parameters remaining unchanged), leading to a revised sample size of 2600 patients
(1300 patients per group).
This change was recommended by the TSC after the internal pilot feasibility assessment noted that the
recorded duration of vasopressors in the usual-care group was lower than expected, suggesting that
the difference in treatment (and hence outcome) between arms may be smaller than initially anticipated.
Internal pilot
A feasibility assessment was conducted after the end of the internal pilot (i.e. at the first 6 months of
the trial recruitment period) against the following progression criteria:
l separation between groups of 10 mg (noradrenaline equivalent) in mean total vasopressor dose
and/or a separation of 5 mmHg in peak MAP while receiving vasopressors
l a minimum of 50 sites open to recruitment
l the recruitment rate in open sites is at least 80% of the level anticipated.
Interim analyses
A single interim analysis of 90-day mortality was performed following the recruitment and follow-up
to 90 days of 500 patients and reviewed by the DMEC. The interim analysis was conducted using
a Haybittle–Peto stopping rule (p < 0.001) to guide recommendations for early termination due to
either effectiveness or harm. The trial statistician, senior statistician and DMEC were not blinded to
treatment allocation. All other investigators remained unaware of the results of the interim analysis,
other than the recommendation of the DMEC to continue or to terminate recruitment.
Clinical effectiveness analysis
Timing of final analysis
The end of the trial was when the final patient recruited had completed their 90-day follow-up
questionnaire. Following the end of the trial, any patients remaining in follow-up were censored,
the trial database was locked and the final analysis was conducted.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
Timing of outcome assessments
The timings of all outcome assessments were taken relative to the date of randomisation.
Screening data
Based on data from screening and enrolment logs, the following summaries are presented:
l the total number of days of screening (calculated as the sum of the number of days of screening at
each site)
l the number of screened patients
l the number of eligible patients (and per cent of patients screened)
l the number of recruited patients (and per cent of patients eligible) and reasons for non-recruitment,
where known.
The recruitment rate per site per month, defined as number of recruited patients/(total number of days
screening × 12/365), was calculated both overall and by site and summarised across sites by the
median [interquartile range (IQR)].
Recruitment and consent data
A CONSORT (Consolidated Standards of Reporting Trials) flow diagram39 was used to summarise the
patient flow as follows:
l The number of patients aged ≥ 65 years with vasodilatory hypotension and receiving vasopressors
screened, including the number of patients who:
¢ did not meet inclusion criteria (with reasons)
¢ met an exclusion criterion (with reasons)
¢ were eligible but did not undergo randomisation (with reasons).
l The number of patients randomised.
l The number of patients included in the primary outcome analysis (with reasons for those
not included).
l The numbers of patients returning a complete follow-up questionnaire at 90 days and 1 year.
The number and percentage of patients who had capacity at randomisation and gave consent was
reported for each treatment group. Subsequent consent procedures were summarised in a flow
diagram that included the following information for each treatment group.
l For all patients:
¢ whether or not a consultee (personal or nominated) was approached
¢ whether or not the patient regained capacity prior to a consultee being approached.
l For those where a consultee was approached:
¢ whether or not the consultee gave agreement to continue trial participation, for access to
medical records for ongoing data collection and to receive follow-up questionnaires or any other
outcome of the approach
¢ whether or not the patient regained capacity before hospital discharge.
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l For those who regained capacity:
¢ whether or not the patient gave consent to continue trial participation, for access to medical
records for ongoing data collection and to receive follow-up questionnaires or any other
outcome of the approach.
l For those discharged prior to consent/opinion being confirmed in hospital, the telephone/postal
approach for consent/opinion was summarised.
Patients for whom consent was not given for continued trial participation (e.g. trial treatment)
were included in the analysis of the primary outcome and all other secondary end points (unless
otherwise specified).
Patients for whom consent was not given to receive follow-up questionnaires had missing data
imputed so that they could be included in the analysis of cognitive decline and HRQoL at 90 days and
1 year (if known to be alive at these time points). These patients were also included in the analysis of
all other end points (unless otherwise specified).
Patients for whom consent was not given for accessing their medical records for ongoing data collection
were included in the reporting of baseline characteristics and trial treatment (as these data were
gathered directly from source on the CRF), but not included in those end points that were collected
using data retrospectively obtained from linked data sets (i.e. duration and days free from organ
support, duration of unit and hospital stay) and were not included in the analysis of patient-reported
outcomes (as these outcomes are reported only for patients known to be alive from medical records).
The patients were censored for mortality end points on the date their consent was withheld.
Baseline patient characteristics
The following baseline demographic and clinical data were summarised for each treatment group,
but not subjected to statistical testing:
l demographics –
¢ age [mean (SD)]
¢ sex (male, female) [number (%)].
l comorbidities [number (%)] –
¢ chronic hypertension (yes, no)
¢ chronic heart failure (yes, no)
¢ atherosclerotic disease (yes, no)
¢ chronic renal replacement therapy at ICU admission (yes, no).
l dependency prior to admission to acute hospital (e.g. able to live without assistance in daily
activities, minor/major assistance with daily activities, total assistance with all daily activities)
[number (%)]
l location prior to admission to critical care and urgency of surgery (e.g. emergency department/not
in hospital, theatre elective/scheduled surgery, theatre emergency/urgent surgery, other critical care
unit, ward or intermediate care area) [number (%)]
l acute severity of illness from first 24 hours following admission to the unit –
¢ Acute Physiology and Chronic Health Evaluation II (APACHE II) score40 [mean (SD)]
¢ ICNARC physiology score41 [mean (SD)]
¢ ICNARCH–2015 model predicted risk of death42 [median (IQR)]
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¢ Sepsis-343,44 (no sepsis, sepsis, septic shock) [number (%)] (note that Sepsis-3 criteria specify that
there must be evidence of infection and two or more points on the Sequential Organ Failure
Assessment score and this categorisation is based on data from the first 24 hours following
admission to the ICU).
l MAP (mmHg) at randomisation [mean (SD)]
l vasopressor infusions received at randomisation [number (%)] –
¢ none [patients in this category were eligible for recruitment prior to version 2.0 of the protocol
if a decision had been taken to start vasopressors or if they had received vasopressors in the
form of metaraminol or terlipressin boluses (see Inclusion criteria)]
¢ noradrenaline equivalent < 0.1 µg/kg/minute
¢ noradrenaline equivalent ≥ 0.1 µg/kg/minute
¢ metaraminol
¢ other/combination.
l duration of vasopressor infusion prior to randomisation (minutes) [median (IQR)].
Protocol adherence
Exposure
Exposure to the intervention was assessed by the following parameters, calculated for each
treatment group:
l MAP – mean (SD) and median (IQR) of the (1) highest and (2) mean MAP for each patient while
receiving vasopressors, and difference in means with 95% CI
l receipt of vasopressors – the number and percentage of patients receiving each vasopressor either
as a continuous infusion or bolus (noradrenaline, adrenaline, dopamine, phenylephrine, vasopressin,
metaraminol, terlipressin)
l duration of vasopressors – mean (SD) and median (IQR) of the total duration (hours) from the later
of the time of randomisation or time of initiation of vasopressors to the end of the first episode
of vasopressors (defined as the start of a 24-hour period during which the patient received no
vasopressors), critical care discharge or death (whichever comes first), and difference in means
with 95% CI
l dose/rate of vasopressors when given as a continuous infusion – mean (SD) and median (IQR) of the
(1) highest and (2) mean rate of noradrenaline equivalents (µg/kg/minute) and metaraminol (mg/hour),
and difference in means with 95% CI
l total dose of vasopressors (from either infusion or bolus) – the median (IQR) among patients
receiving the relevant vasopressor(s) and mean (SD) among all patients (including those not receiving
the vasopressors with a value of zero) of the total dose (mg) of vasopressors for (1) noradrenaline,
adrenaline, dopamine, phenylephrine and vasopressin combined, expressed as noradrenaline
equivalent (see below), (2) metaraminol and (3) terlipressin, and difference in means with 95% CI
l total number of episodes of vasopressor treatment (recommencing vasopressors after 24 hours
without vasopressor treatment defines the start of a new episode) – mean (SD) and median (IQR) of
the number of vasopressor treatment episodes at critical care discharge, and difference in means
with 95% CI
l total number of days on vasopressors at critical care discharge – mean (SD) and median (IQR) of the
total number of days on vasopressors, and difference in means with 95% CI
l fluid balance – mean (SD) and median (IQR) of fluid balance (ml), measured as the cumulative sum
of daily fluid balance during the first episode of vasopressor treatment
l urine output – mean (SD) and median (IQR) of the mean daily urine output (ml/kg/hour) during the
first episode of vasopressor treatment.
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The distribution across patients of the daily values of the following parameters in each group was
presented in the form of box and whisker plots for days 1–7 following randomisation among all
patients receiving vasopressors on that day:
l MAP – (1) highest and (2) mean MAP for each patient while receiving vasopressors
l dose/rate of vasopressor infusion – (1) highest and (2) mean rate of noradrenaline equivalents
(µg/kg/minute) and metaraminol (mg/hour)
l daily fluid balance (ml)
l daily urine output (ml/kg/hour).
The numbers of patients included on each day was reported at the foot of the figure. Patients were
included in these summaries only if they had recorded treatment data up to discontinuation or death
on treatment. Time to discontinuation of vasopressors was illustrated using Kaplan–Meier curves by
group, with time measured in hourly intervals from randomisation (rounded down to the nearest whole
hour). Time of discontinuation was defined as the start of the first period of 24 consecutive hours not
on vasopressors, or the time of death for patients who died on treatment without having achieved 24
continuous hours free of vasopressors. Patients without recorded treatment data up to discontinuation
or death on treatment were censored at the time of last recorded treatment.
Noradrenaline-equivalent doses were calculated using the two alternate conversion methods (Table 3).
Data on vasopressor infusions were collected on an hourly basis. Accordingly, to calculate total dose,
each recorded infusion episode was assumed to last for exactly 1 hour. Analysis using the calculations
from method 145 of Table 3 were used for the main results paper for this trial and corresponding
analysis using calculations from method 246 was used in a sensitivity analysis.
A number of different exploratory graphical approaches were used to further visually summarise
treatment pathways by arm. These did not incorporate any formal statistical comparisons beyond those
specified in this statistical analysis plan.





Adrenaline µg/kg/minute × 1
Dopamine µg/kg/minute /150
Phenylephrine µg/kg/minute × 0.1
Vasopressin U/minute × 2.5
Method 246
Adrenaline µg/kg/minute × 1
Dopamine µg/kg/minute × 0.01
Phenylephrine µg/kg/minute × 0.45
Vasopressin U/minute × 5 × 100/weight (kg)
U, units.
Reproduced with permission from Thomas et al.47
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
20
Protocol deviations
Failure to discontinue vasopressors or reduce the dose/rate once MAP was above the upper limit of
the MAP target range (i.e. 65 mmHg) for at least 3 consecutive hours in the permissive hypotension
group defined a potential protocol deviation (with no treatment protocol deviation defined in the
usual care group). Potential protocol deviations, identified from the trial data, triggered a query to
the participating site, which had the opportunity to provide a justification. In some cases, the TMG
determined that the event did not constitute a protocol deviation (e.g. MAP values may have been
above range only transiently on the hour but within range between the hourly recordings in the trial
data). The total number of such events that were decided not to constitute a deviation is reported.
Likewise, the number and percentage of patients with at least one protocol deviation in the permissive
hypotension group is reported. Adherence was defined at the patient level as not having experienced
any protocol deviation.
For each patient in the permissive hypotension group, the following measures of protocol adherence
were also calculated: total time on vasopressors with recorded MAP within target range, total time on
vasopressors with recorded MAP above target range, total time on vasopressors with recorded MAP of
> 5 mmHg above upper limit of target and total time on vasopressors with recorded MAP below target
range. These measures were summarised as mean (SD) or median (IQR) in patients with recorded
treatment data up to discontinuation or death on treatment.
Co-interventions
The following parameters were calculated for each treatment group in patients with recorded
treatment data up to discontinuation or death on treatment:
l receipt of inotropes – the number and percentage of patients receiving inotropes (i.e. any of
dobutamine, milrinone or levosimendan) at any time during the first recorded episode of
vasopressor treatment
l receipt of corticosteroids – the number and percentage of patients receiving corticosteroids at any
time during the first recorded episode of vasopressor treatment.
Serious adverse events
The numbers of SAEs and number and percentage of patients experiencing each SAE following
randomisation until critical care discharge is reported in each treatment group. The total number of
patients experiencing one or more SAE is compared between groups using Fisher’s exact test.
Withdrawal/follow-up
The number and percentage of patients withdrawing consent (or consultees withdrawing agreement)
to trial participation is reported in each group, with reasons provided. Data collected up until the
point of withdrawal are included in the analysis, but no further data after the date of withdrawal were
collected for that patient.
The number and percentage of patients lost to follow-up for mortality at 90 days (as a percentage of all
randomised patients) and for questionnaire outcomes (as a percentage of survivors) at 90 days and
1 year are reported for each group. The total lost to follow-up for mortality includes consented patients
for whom data are unavailable (i.e. true loss to follow-up), those who withdrew before 90 days and those
for whom consent to access medical records for ongoing data collection was refused before 90 days.
The total lost to follow-up for 90-day questionnaire follow-up includes consented patients for whom data
are unavailable (i.e. true loss to follow-up), those who withdrew and those for whom consent to receive
questionnaires was never given. The baseline characteristics (as described in Baseline patient characteristics)
of patients completing a follow-up questionnaire at each time point were compared with those of patients
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who did not complete a follow-up questionnaire who were known to be alive at that time point. The same
approach was taken for 1-year questionnaires (note that 1-year follow-up is truncated).
Analysis methods
The primary outcome of number and percentage of deaths by 90 days following randomisation is
reported. The primary effect estimate is the absolute risk reduction, reported with a 95% CI. The
relative risk is also reported. Deaths by 90 days following randomisation are compared between the
groups, unadjusted and using Fisher’s exact test. Owing to the anticipated low amount of clustering,
unadjusted analyses did not take account of site-level effects.
An analysis, adjusted for baseline data, was also conducted using multilevel logistic regression with a




l dependency prior to admission to acute hospital
l location prior to admission to critical care and urgency of surgery
l ICNARC physiology score (linear)41
l Sepsis-344
l vasopressors received as a continuous infusion at randomisation
l duration of vasopressors prior to randomisation (linear).
(All categorical variables are defined and grouped as previously described under Baseline patient
characteristics.)
Baseline variables were selected for inclusion in the adjusted analysis according to anticipated
relationship with outcome. The results of the multilevel logistic regression model are reported as an
adjusted odds ratio with 95% CI. The unadjusted odds ratio is presented for comparison.
The primary outcome (i.e. 90-day mortality) is analysed by the following prespecified patient subgroups:
l age (linear)
l chronic hypertension (yes, no)
l chronic heart failure (yes, no)
l atherosclerotic disease (yes, no)
l predicted log-odds of acute hospital mortality from the ICNARCH–2015 risk prediction model (linear)42
l Sepsis-344
l vasopressors received at randomisation (see Baseline patient characteristics).
These analyses tested for an interaction between the subgroup categories (or subgroup variable for linear
interactions) and the treatment group in a multilevel logistic regression model, adjusted for the same
baseline variables as the primary analysis. For linear interactions, the interaction effect was illustrated by
calculating the adjusted odds ratio within five categories at quintiles of the continuous variable.48
The primary analysis was repeated, adjusting for adherence to allocated intervention (i.e. binary variable
equal to zero for all patients allocated permissive hypotension with one or more recorded protocol
deviation, and 1 for all other patients) and using a structural mean model with an instrumental variable of
allocated treatment to estimate the complier-average causal effect of treatment.49
An additional sensitivity analysis was performed, repeating the primary analysis in the subset of
patients who would have been eligible for the trial following the inclusion criteria as defined in the
protocol amendment to version 2.0 (i.e. patients restricted to those who had started vasopressors
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between 1 and 6 hours prior to randomisation, and excluding any patients who were receiving only
noradrenaline at randomisation at a dose level of < 0.1 µg/kg/minute).
Secondary outcomes are reported by treatment group. Continuous outcomes are reported using either
mean and SDs (for duration of advanced respiratory support for all patients, duration of renal support
for all patients, number of days alive and free of advanced respiratory support to day 28, number
of days alive and free of renal support to day 28, and IQCODE scores at 90 days and at 1 year) or
median and IQR (for duration of advanced respiratory support in patients who received it, duration
of renal support in patients who received it, and duration of critical care and acute hospital stay).
Unadjusted comparisons of continuous outcomes are made using t-tests or Wilcoxon rank-sum tests
(comparisons for duration of stay were stratified by survival status at discharge). Adjusted comparisons
(for all continuous variables excluding duration of stay) are made using multilevel linear regression,
adjusted for the same baseline variables as the adjusted analysis of the primary outcome, using
bootstrapping to account for anticipated non-normality in the distribution.50
Binary outcomes (i.e. mortality at discharge from critical care unit and acute hospital) are reported
using numbers and percentages. Unadjusted comparisons were made using Fisher’s exact test and
adjusted comparisons using multilevel logistic regression (adjusted for the same baseline variables as
the adjusted analysis of the primary outcome).
Time-to-event outcomes (i.e. duration of survival to longest available follow-up) are reported using
Kaplan–Meier curves and compared using the log-rank test. An adjusted comparison was performed
using a Cox proportional hazards model adjusted for the same baseline variables as the primary
analysis, with shared frailty at the site level.
A subgroup analysis of the in-hospital secondary outcomes was performed to compare unadjusted and
adjusted secondary outcomes in those patients who did/did not have chronic hypertension at baseline.
Handling of missing data
The number of missing clinical primary outcome data was anticipated to be small, but is accounted
for in a sensitivity analysis. The primary analysis was repeated once, assuming that all patients in the
intervention group with missing outcomes survived and all patients in the usual-care group with
missing outcomes did not survive. The analysis was then repeated with the opposite assumptions.
This gives the absolute range of how much the results could change if the data were complete.
Analysis of cognitive decline at 90 days and 1 year was carried out once, using only patients with
non-missing data (defined as having no more than three missing items from the 16-item IQCODE) and
then repeating with missing data imputed among patients known to be alive at those time points,
excluding those who did not consent to access of their medical records. Where necessary, missing data
in baseline variables included in the adjusted models were also imputed.
Multiple imputation was undertaken using the multivariate imputation using chained equations
algorithm, with the model including all baseline variables included in the adjusted models and all
outcome variables. Twenty multiply imputed data sets were generated. Models were fitted in each
imputed data set and results combined using Rubin’s rules.51
Expert elicitation methods
The 65 trial primary analysis uses the assumption that missing HRQoL outcomes are ‘missing at
random’ (MAR). This assumes that the probability that a patient’s outcome is missing is not dependent
on the outcome of the patient after conditioning using observed variables, for example the patient’s
characteristics at baseline. Sensitivity analysis that allows patients’ predicted health state to affect the
probability that they return their questionnaire was carried out. For example, we may expect that patients
who are in a relatively good state of health may be more likely to complete and return the HRQoL
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questionnaire, and this would mean that these outcome data may be ‘missing not at random’ (MNAR).
The steps in the expert elicitation framework52 were followed for this additional analysis. These steps
included (1) scoping a 65 trial-specific elicitation exercise, (2) development of an elicitation tool (including
questions about the HRQoL outcomes), (3) eliciting expert opinion, (4) evaluating the elicitation results and
(5) carrying out the sensitivity analysis, incorporating the elicited expert information.
To model the MNAR data53 fully, Bayesian pattern-mixture models were used, which allow calculation
of a patient’s outcome differently, depending on whether the outcome is observed (pattern 1) or
missing (pattern 2):
1. The observed data were used to calculate the outcome using the same statistical model as specified
for the primary analysis.
2. A specified offset (sensitivity parameter) from the mean of the observed data was used to adjust
this model. This sensitivity parameter is able to alter by treatment.54
As some patients did not complete and return a HRQoL questionnaire, which lead to missing outcomes, we
can interpret an offset as the HRQoL difference between these two groups of patients (i.e. those who did
and did not return a questionnaire). As we cannot estimate the offsets from the observed data, expert
opinion about patients’ likely HRQoL values is needed to inform the prior distributions of these parameters.
For all other unknown parameters specified in the model, minimally informative priors were used.
Pattern-mixture models for the HRQoL and the cost-effectiveness analysis (CEA) were fitted using
WinBUGS version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK) (HRQoL) and JAGS software version 4.3.0.55
In the HRQoL models, the random effects were not hierarchically centred, which improved the mixing
of the Markov chain Monte Carlo chains. For the CEA, there were no random effects and the QALYs
and costs were modelled jointly, consistent with the primary analysis. The costs include intervention and
hospital costs, but exclude health services questionnaire costs. There are no missing costs.
Shiny, a web application framework within the statistical software R (The R Foundation for Statistical
Computing, Vienna, Austria), was used to create a 65 trial-specific elicitation tool. This tool was based
on the tool that was developed for the POPPI [Psychological Outcomes following a nurse-led
Preventative Psychological Intervention for critically ill patients (POPPI)] trial.56 The tool was updated
iteratively during a piloting phase.
The experts’ opinions were able to be represented as a split normal distribution (truncated) by utlising
three individual sliders that indicate the following: (1) which they thought the most likely value (mode),
and (2 and 3) their uncertainty about the ‘most likely’ value (left and right SD). Experts were asked to
imagine a group consisting of 100 patients included in the 65 trial, each patient had the same defined
baseline characteristics (i.e. male, an APACHE II score equal to 19 and aged 74 years), was allocated to
the usual-care group and had completed/returned a questionnaire. The experts were then shown a
scale that indicated for this group of 100 patients, based on early trial data, our best estimate of the
average (indicated with an arrow). The experts were then prompted to indicate their thoughts about
the possible average score for an additional five groups that consisted of 100 patients who were
similar to the index group except:
l Group 1 – patients aged ≥ 10 years.
l Group 2 – patients who were female.
l Group 3 – patients who had an APACHE II score of 26.
l Group 4 – patients who failed to complete/return a questionnaire.
l Group 5 – patients allocated to the permissive hypotension group who failed to complete/return
a questionnaire.
Groups 1–3 allowed assessment of how closely an expert’s elicited values are calibrated with outcomes
that are known empirically. Groups 4 and 5 informed sensitivity parameter priors.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
Once this step was completed, graphical feedback was provided that indicated any differences/overlap
in their opinions about groups 4 and 5. If this indicated unreasonable answers, the expert was then
given the option of revising their answers. Experts were then given additional new information about
group 4 (i.e. usual-care group patients) and asked to reconsider the answers they had given for group 5
(i.e. permissive hypotension group patients). This allowed for the prospect that the elicited values for
usual-care group patients who failed to complete/return a questionnaire were related to the permissive
hypotension group patients who also failed to complete/return a questionnaire. This enabled construction
of a joint distribution for each groups’ sensitivity parameters, allowing correlation between the groups.
Important context to understand experts’ reasons for their views was collected using free-text question
fields. This also enabled us to assess the reliability of experts’ responses to the previous questions.
The HRQoL scores were shown on a numeric scale from –28 to 100 (original EQ-5D-5L utility score
scale multiplied by 100), anchored at 0 for ‘death’ and 100 for ‘perfect health’. A HRQoL score is
calculated from a patient’s answers to five questions about (1) mobility, (2) self-care, (3) usual activities,
(4) pain or discomfort and (5) anxiety or depression. Initially, an arrow shows the point on the scale
linked to all the answers being ‘no problems’ (100). Using drop-down menus with the five available
levels of severity, the expert may select other combinations of answers. The arrow then moves to show
how the HRQoL score changes.
The 65 trial chief investigator (PRM) e-mailed contacts at the participating sites, inviting them to
identify individuals who are involved in long-term patient follow-up. ICNARC then sent these
individuals a PIS and a link to the elicitation tool. A maximum of two reminders to complete the
questionnaire were sent via e-mail, with consent taken electronically as part of the elicitation tool.
Two statisticians (AJM and DH) independently examined the elicited information using prespecified
criteria to identify those experts whose responses were ‘usable’. Of the usable responses from experts,
responses were further categorised as ‘high’ and ‘very high’ in confidence (separated into two distinct
subgroups). This was designed to identify any expert who had clearly misunderstood the exercise.
Consistency in both quantitative and qualitative responses was required to be included within the
high-confidence group. When agreement was observed between the expert’s views about groups 1–3
and the ‘truth’ (based on trial data), the expert was included within the very high-confidence group. The
categorisations of the two statisticians were compared and, through discussion, discrepancies were resolved.
Following the approach discussed in Mason et al.,52 we used a combination of pooled and individual
priors to fully explore the sensitivity of the trial results to a range of expert opinion. The individual
priors were selected from the very high-confidence subgroup.
We ran all models using two chains initialised to diffuse starting values to produce a sample of
100,000 after convergence for posterior inference. Convergence was assumed if the Gelman–Rubin
convergence statistic57 for individual parameters was < 1.05 and a visual inspection of the trace plot
for each parameter was satisfactory. The results from the Bayesian MNAR sensitivity analyses are
compared with Bayesian MAR and complete-case analysis.
Statistical software
The analyses were conducted in Stata/SE version 14.2. Other packages, such as R, were used for
specific analyses.
Health economics analysis
Statistical analysis of cost-effectiveness analysis at 90 days
Following recent NICE recommendations, the CEAs adopted a NHS and Personal Social Services
perspective, and reported costs and QALYs. The EQ-5D-5L measure has been used for assessing
the health status of each trial participant, which was valued using the valuation set for England32
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to calculate the EQ-5D-5L index score. The QALY gain was calculated by combining survival data with
EQ-5D-5L index scores. The corresponding INMB was estimated by valuing incremental QALYs at the
NICE-recommended threshold (i.e. £20,000) for a QALY gain and subtracting incremental costs.
In line with best practice for the analysis of RCTs, the CEA followed the intention-to-treat principle58
and reported incremental costs, QALYs and cost-effectiveness up to 90 days, according to randomised
group. Missing data are a common occurrence within RCTs, but often health economic analyses
alongside RCTs fail to apply appropriate methods to address missing data. In this analysis, missing
data in baseline covariates, resource use and outcomes (Table 4) were handled with multivariate
imputation by chained equation.60 Under this approach, each missing variable was imputed conditional
on fully observed baseline variables (such as age, sex, chronic hypertension, chronic heart failure,
atherosclerotic disease, dependency prior to admission to acute hospital, source of admission, ICNARC
model physiology score, sepsis, septic shock, vasopressors received at randomisation, duration of
vasopressor infusion prior to randomisation) and all other imputed variables. Missing data from follow-up
EQ-5D-5L and health services questionnaires were imputed from patients who were eligible and who
had fully completed those questionnaires. Missing/incomplete EQ-5D-5L scores of patients who did not
return or fully complete the EQ-5D-5L questionnaire administered at 90 days were imputed from those
survivors who did fully complete the questionnaire. Similarly, for those eligible patients who did not
return the health services questionnaire, information on the use of health services up to 90 days post
randomisation was imputed from those patients who completed this questionnaire. The CEA used
bivariate seemingly unrelated regression model, which is a system of unrelated regression equations on
the costs and effectiveness (QALY) component of the analysis, allowing for correlation between costs
and QALYs. The economic analysis adjusted for same baseline covariates as for the clinical analysis to
adjust for baseline imbalances between the randomised arms (see Clinical effectiveness analysis).
Analysis of uncertainty and sensitivity in cost-effectiveness
The incremental costs and QALYs were estimated using a single-level bivariate seemingly unrelated
regression model. To express the uncertainty in the estimation of the incremental costs and QALYs,
we generated 800 estimates of incremental costs and QALYs from the joint distribution of estimated
incremental costs and QALYs from single-level regression model, assuming asymptotic normality. These
incremental costs and QALYs were then plotted on the cost-effectiveness plane to summarise the joint
uncertainties in incremental costs and QALYs.61 From the joint distribution of incremental costs and
QALYs, we have derived the cost-effectiveness acceptability curves by calculating the probability that,
compared with usual care, the permissive hypotension intervention is cost-effective, given the data,
at alternative levels of willingness to pay for a QALY gain.
The main assumptions made in the base-case scenario and how each was relaxed in sensitivity analyses
are detailed below and summarised in Table 5.
Health-related quality of life from crosswalk value set
The base-case HRQoL was valued using EQ-5D-5L value sets for England defined by the EQ-5D-5L
descriptive system.32 An alternative approach to using the EQ-5D-5L value sets is to use validated
mapping function to derive utility values for the EQ-5D-5L from the more traditional EuroQol-5
Dimensions, three-level version, value set.62 To examine the sensitivity of the results to the choice of
approach in the sensitivity analysis, HRQoL was estimated by mapping the five-level descriptive system
onto the three-level valuation system using the mapping function developed by van Hout et al.30,63
Readmissions from the health services questionnaire
The base-case analysis included readmissions to critical care recorded on the CMP database and also
those recorded from responses to the health services questionnaire. The readmission costs to critical
care could thereby be double counted. To consider the possible impact of double counting the same
readmissions across both data sources, we have included only readmissions from the CMP database in
the sensitivity analysis.
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TABLE 5 Alternative assumptions for the CEA sensitivity analyses
Assumption Base case Sensitivity analysis
HRQoL valuation EQ-5D-5L value set was applied Crosswalk (between EQ-5D-3L
and EQ-5D-5L) value set was
applied
Readmissions from the health services
questionnaire
Included in the analysis Excluded from the analysis
Distributional assumptions Costs and QALYs normally
distributed
Costs and QALYs gamma
distributed
EQ-5D-3L, EuroQol-5 Dimensions, three-level version.
TABLE 4 Variables considered for multiple imputation and form of imputation model
Variable
Missing values in patients with
known primary outcome, n (%) Imputation model
Patient-level covariatesa
Allocated treatment group 0 (0) None required
Age 0 (0) None required
Sex 9 (< 0.1) Logistic regression
Chronic hypertension 0 (0) None required
Chronic heart failure 1 (< 0.1) Logistic regression
Atherosclerotic disease 0 (0) None required
Dependency prior to admission to
acute hospital
23 (< 0.1) Multinomial logistic regression
Source of admission 6 (< 0.1) Multinomial logistic regression
ICNARC physiology score 12 (< 0.1) Predictive mean matching
Sepsis/septic shock 9 (< 0.1) Logistic regression
Vasopressors received at
randomisation
35 (1.4) Multinomial logistic regression
Duration of vasopressor infusion
prior to randomisation
71 (2.9) Predictive mean matching
Outcomes and resource use at 90 daysb
IQCODE score 458 (18.6) Predictive mean matching
EQ-5D-5L health utility 444 (18.0) Predictive mean matching
Health services questionnaire costs 766 (31.2) Predictive mean matching
Outcomes and resource use at 1 yearc
IQCODE score 302 (15.1) Predictive mean matching
EQ-5D-5L health utility 309 (15.4) Predictive mean matching
Health services questionnaire costs 445 (22.3) Predictive mean matching
a All patients (n= 2463) with non-missing primary outcome data at 90 days.
b Reported for all patients with non-missing primary outcome data, minus seven patients who had missing hospital
length of stay data.
c Total number of eligible patients for 1-year outcomes was 1999, which is all eligible patients for outcomes and
resource use at 90 days (n = 2456) minus censored cases (because of administrative reasons) (n= 456) and
withdrawals at 1 year (n = 1).
Reproduced with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.
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Distributional assumptions for costs and quality-adjusted life-years
The base-case regression model assumed that costs and QALYs were normally distributed. In
sensitivity analyses, we assessed the robustness of the cost-effectiveness results to alternative
distributional assumptions about both cost-effectiveness end points. Following methodological
guidance,30,58 a gamma distribution for costs and QALYs was considered in the sensitivity analysis.
Gamma distribution was considered in the sensitivity analysis because costs had a right-skewed
distribution64 and QALYs had anticipated large proportion of decedents with zero QALYs, and the
remainder of the distribution was right skewed.
The results of the sensitivity analysis were reported as mean INMBs with corresponding 95% CIs.
Cost-effectiveness analysis by subgroups at 90 days
Prespecified subgroup analyses were conducted for the same subgroups that were considered in the
clinical effectiveness evaluation (see Analysis methods). The above seemingly unrelated regression
models were expanded to include subgroup by randomised arm interaction terms65 and used to report
INMB at 90 days by subgroups.
Cost-effectiveness outcomes at 1 year
Use of health-care resources (e.g. critical care, general medical length of stay, outpatient and
community care) between 90 days and 1 year was measured using readmission information from the
CMP and health services questionnaires at 1 year. Total costs at 1 year were estimated by valuing
resource with appropriate unit costs. Life-years up to 1 year was reported using the follow-up survival
data. HRQoL data up to 1 year were combined with survival data to report QALYs at 1 year. For
patients surviving up to 1 year, we used EQ-5D-5L responses at 1 year, assuming a linear interpolation
between the EQ-5D-5L scores at 90 days and 1 year. For decedents between 90 days and 1 year,
where an EQ-5D-5L score at 90 days was available, a linear interpolation was applied between the
90-day EQ-5D-5L and the date of death (when a zero EQ-5D-5L score was applied).
As not all randomised patients were followed up to 1 year, their survival, resource use and HRQoL
data were censored. Any administrative censoring at 1 year of resource use, survival and HRQoL was
assumed at random. The statistical analysis of CEA end points at 1 year followed the same approaches
that are outlined for the 90 days end point.
METHODS





Relative to the target of 65 sites, expressions of interest to participate were received from 124 NHS
adult general critical care units across England, Wales and Northern Ireland. Of these, 101 completed
a site feasibility questionnaire and were considered for participation by the ICNARC CTU. A total of
67 sites were invited to participate and were chosen based on a variety of factors, including geography,
good research track record in previous multicentre RCTs, display of enthusiasm for the trial and
adequate research nurse support. Two selected sites ultimately did not open (one had two critical care
units within their trust and focused resources on delivering the trial in one and the other had a change
in local priorities, limiting research participation).
Site set-up
The full site target was reached, with all 65 sites recruiting patients into the 65 trial. The first sites
opened in July 2017, 2 months ahead of schedule, with the final site opening in September 2018
(Figure 2). By the end of the internal pilot, 59 sites were open to recruitment.
From a research governance perspective, the median time from provision of the final local information
pack to the issuing of local confirmation of capacity and capability was 70 (IQR 44–129) days. The median
time from local confirmation of capacity and capability to the start of patient screening at sites was
20 (IQR 5–49) days. The median time from the start of patient screening to the first patient recruited at
sites was 9 (IQR 3–21) days. Overall, the whole process from site selection to first patient recruited
took a median of 132 (IQR 83–169) days.
Each site participated in the 65 trial for a median of 18 (IQR 17–19) months. Of the 65 sites that
opened, seven were closed early. Reasons for closing early included lack of equipoise (n = 2), lack of
research nurse resources (n = 2), low recruitment (n = 2) and reaching the contractual recruitment





























































































































































FIGURE 2 Actual vs. expected number of sites opening to recruitment. Reproduced with permission from Lamontagne
et al.59 Copyright © 2020 American Medical Association.
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Patient screening, randomisation and consent
Screening and randomisation
Between 3 July 2017 and 16 March 2019, a total of 10,755 patients aged ≥ 65 years receiving
vasopressors for vasodilatory hypotension were screened across the 65 sites (Figures 3 and 4).
Of these patients, just under 40% (n = 4271) did not meet inclusion criteria. Of those patients meeting
inclusion criteria, just under 50% (n = 3066) met one or more exclusion criteria [the most common
being ongoing treatment for brain injury (n = 1033) and death perceived as imminent (n = 690)].
Around 5% (n = 330) of eligible patients did not undergo randomisation. Reasons for not randomising
eligible patients ranged mainly from clinician decisions (e.g. some decided that certain patients required
a higher MAP target) to very few patient decisions (e.g. a small number of patients with capacity
prospectively declined participation). As a result, 2600 patients were randomised (Table 6) and after
excluding two duplicates (two patients were randomised twice and only the first randomisation was
kept for analysis) there were 1291 patients allocated to the permissive hypotension group and 1307
patients allocated to the usual-care group.
The overall site recruitment rate was 2.4 patients per month with a median recruitment rate of 2.1
(IQR 1.0–3.1) patients across sites. Many were able to embed 65 trial screening and randomisation into
routine clinical practice, leading to a high proportion of randomisations occurring outside standard
office working days and hours (Figures 5 and 6).
Consent
Of the 2598 unique patients, 15 (permissive hypotension, n = 8; usual care, n = 7) requested that all
data be removed from the trial and are not included in further reporting or analysis. For the remaining
2583 patients, consent for ongoing data collection and linkage was obtained for 2461 (95%). A further
five patients (or their consultees) declined consent after 90 days and were included in the analysis up
to that point. By 90 days, a further two patients had withdrawn consent, leaving 2464 eligible for
inclusion in the analysis of the primary outcome. Consent and withdrawal rates by 90 days did not
differ by randomised group. The full flow of the consent procedures, according to randomised groups,
is shown in Figures 7 and 8.
Baseline characteristics
The randomised groups were well matched at baseline (Table 7). In both groups, patients had a mean
age of 75 years and over half were male (permissive hypotension, 57.2%; usual care, 55.9%). Just under
half (46%) of patients in both groups had known chronic hypertension and around one-third were
admitted to critical care from the emergency department (or not in hospital). The proportion of
patients requiring assistance with daily activities of living showed some differences, with 417 (34.4%)
patients in the permissive hypotension group compared with 380 (30.9%) patients in the usual-care
group. Patients were randomised at a median of 3.1 hours after commencing vasopressors.
Clinical management
Vasopressors
Following randomisation and during the first episode of vasopressors, patients in the permissive hypotension
group had a lower exposure to vasopressors than those in the usual-care group. Mean duration of
vasopressors in the permissive hypotension group was 46.0 (SD 52.4) hours, compared with 55.9 (SD 60.8)
hours in the usual-care group (difference −9.9 hours, 95% CI −14.3 to −5.5 hours). Time to discontinuation
of vasopressors is shown in Figure 9. The mean total of vasopressors (noradrenaline equivalent) in the
permissive hypotension group was 31.5 mg compared with 44.3 mg for the usual-care group (difference
−12.8 mg, 95% CI −18.0 mg to −7.6 mg). For patients receiving metaraminol, the mean difference in
metaraminol total dose was –4.1 mg (95% CI –8.3 mg to –0.0 mg). Both groups had a similar number of
episodes of vasopressors, the majority with a single episode [permissive hypotension, n = 1094 (86.8%);
RESULTS
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Allocated to the permissive
hypotension group
(n = 1291)
Allocated to the usual
care group
(n = 1307)
Included in primary outcome analysis
(n = 1221, 95%)
Included in primary outcome analysis
(n = 1242, 96%)
Returned a completed questionnaire
(n = 261; 70% of those sent a
questionnaire at 1 year)
Returned a completed questionnaire
(n = 533; 80% of those sent a
questionnaire at 90 days)
Returned a completed questionnaire
(n = 493; 75% of those sent a
questionnaire at 90 days)
Returned a completed questionnaire
(n = 255; 69% of those sent a
questionnaire at 1 year)
• Refused retrospective consent prior to 90 days, n = 69
• Withdrew consent, n = 1
• Were lost to follow-up for primary outcome, n = 0
• Refused retrospective consent prior to 90 days, n = 63
• Withdrew consent, n = 1
• Was lost to follow-up for primary outcome, n = 1
Duplicate patients (only first randomisation included in analysis)
(n = 2)
• Were deemed to need a higher MAP target, n = 122
• Had treatment limitations in place, n = 30
• Patient refused consent prior to randomisation, n = 20
• Had a family member decline consent prior to randomisation, n = 11
• Were on a study where co-enrolment was not permitted, n = 5
• Had other reasons, n = 142
Did not meet inclusion criteria
(n = 4271)
Met ≥ 1 exclusion criteriaa
(n = 3066)
Eligible but did not undergo randomisation
(n = 330)
• Started vasopressors ≥ 6 hours ago, n = 1808
• Received noradrenaline at a dose of < 0.1 μg/kg/minute, n = 1482
• Expected to continue vasopressors for < 6 hours, n = 981
• Had ongoing treatment for brain injury, n = 1033
• Had vasopressors given solely for acute ventricular failure, n = 776
• Had death perceived as imminent, n = 690
• Had vasopressors given solely for bleeding, n = 496
• Had ongoing treatment for spinal cord injury, n = 131
• Were previously enrolled in the 65 trial, n = 60
• Had vasopressors given solely for post-cardiopulmonary bypass
    vasoplegia, n = 32
FIGURE 3 A CONSORT (Consolidated Standards of Reporting Trials) flow diagram of screening, randomisation and
follow-up through the 65 trial. a, Patients are included in more than one category if they met more than one exclusion
criteria. Reproduced with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.
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FIGURE 4 Recruitment over time: actual and pre-trial estimate. Reproduced with permission from Lamontagne et al.59
Copyright © 2020 American Medical Association.






Dorset County Hospital (Dorset, UK) July 2017 668 32
Musgrove Park Hospital (Taunton, UK) July 2017 721 70
Peterborough City Hospital (Peterborough, UK) July 2017 609 50
Poole Hospital (Poole, UK) July 2017 635 72
Salford Royal Hospital (Salford, UK) July 2017 1914 20
King’s College Hospital (London, UK) July 2017 1524 21
Russells Hall Hospital (Dudley, UK) July 2017 839 96
The York Hospital (York, UK) July 2017 976 15
University Hospital Lewisham (London, UK) July 2017 684 66
Queen Alexandra Hospital (Portsmouth, UK) July 2017 1115 80
Royal Cornwall Hospital (Cornwall, UK) July 2017 795 2
Warwick Hospital (Warwick, UK) July 2017 374 114
William Harvey Hospital (Ashford, UK) July 2017 849 56
Basingstoke and North Hampshire Hospital
(Basingstoke, UK)
July 2017 934 41
Princess Royal University Hospital
(Orpington, UK)
July 2017 599 47
Ipswich Hospital (Ipswich, UK) July 2017 754 58
Bristol Royal Infirmary (Bristol, UK) July 2017 1073 38
Medway Maritime Hospital (Kent, UK) August 2017 472 56
Manchester Royal Infirmary (Manchester, UK) August 2017 2303 23
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Morriston Hospital (Swansea, UK) August 2017 1211 37
Broomfield Hospital (Chelmsford, UK) August 2017 722 46
TunbridgeWells Hospital (TunbridgeWells, UK) August 2017 485 84
Addenbrooke’s Hospital (Cambridge, UK) August 2017 830 38
Royal Stoke University Hospital
(Stoke-on-Trent, UK)
August 2017 1319 40
Countess of Chester Hospital (Chester, UK) August 2017 689 64
Royal Gwent Hospital (Newport, UK) August 2017 895 24
Worthing Hospital (Worthing, UK) September 2017 606 53
Northampton General Hospital
(Northampton, UK)
September 2017 828 33
Derriford Hospital (Plymouth, UK) September 2017 1307 10
Darent Valley Hospital (Dartford, UK) September 2017 635 40
Royal Berkshire Hospital (Reading, UK) September 2017 744 76
Aintree University Hospital (Liverpool, UK) September 2017 1144 67
Royal Glamorgan Hospital (Pontyclun, UK) September 2017 484 35
James Cook University Hospital
(Middlesbrough, UK)
September 2017 1842 20
Queen Elizabeth Hospital (Gateshead, UK) September 2017 863 6
Royal Oldham Hospital (Oldham, UK) September 2017 639 24
Royal Blackburn Hospital (Blackburn, UK) September 2017 1617 43
Charing Cross Hospital (London, UK) September 2017 1092 29
St Mary’s Hospital (London, UK) September 2017 610 15
Southmead Hospital (Bristol, UK) September 2017 2354 95
Royal Devon and Exeter Hospital (Exeter, UK) October 2017 916 23
Altnagelvin Hospital (Londonderry, UK) October 2017 393 6
Darlington Memorial Hospital (Darlington, UK) October 2017 646 50
Glangwili General Hospital (Carmarthen, UK) October 2017 649 106
Hammersmith Hospital (London, UK) October 2017 539 6
Arrowe Park Hospital (Wirral, UK) October 2017 754 11
University Hospital Coventry (Coventry, UK) October 2017 1122 31
Antrim Area Hospital (Antrim, UK) October 2017 359 16
Leicester Royal Infirmary (Leicester, UK) October 2017 1163 46
Pinderfields Hospital (Wakefield, UK) October 2017 799 24
Queen Elizabeth Hospital, Woolwich
(London, UK)
October 2017 774 142
Queens Medical Centre (Nottingham, UK) October 2017 1072 10
Royal Liverpool University Hospital
(Liverpool, UK)
October 2017 1603 17
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October 2017 1281 55
Torbay Hospital (Torquay, UK) November 2017 533 51
Lister Hospital (Stevenage, UK) November 2017 1003 12
Gloucestershire Royal Hospital
(Gloucester, UK)
November 2017 886 47
Royal Preston Hospital (Preston, UK) December 2017 1401 9
Norfolk and Norwich Hospital (Norwich, UK) January 2018 1569 33
North Devon District Hospital (Barnstaple, UK) January 2018 440 6
St Thomas’ Hospital (London, UK) January 2018 1239 9
Blackpool Victoria Hospital (Blackpool, UK) February 2018 733 27
Yeovil District Hospital (Yeovil, UK) February 2018 585 8
Northern General Hospital (Sheffield, UK) March 2018 2324 6
University Hospital of North Tees
(Stockton-on-Tees, UK)
September 2018 684 13
















































FIGURE 5 Randomisation by day of week. Reproduced with permission from Lamontagne et al.59 Copyright © 2020
American Medical Association.
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Yes (n/N = 763/1131)
Yes (n/N = 720/763)
Yes (n/N = 218/224)
Yes (n/N = 224/720) No (n/N = 496/720) No (n/N = 16/43)
No (n/N = 29/368)No (n/N = 8/27)
Yes (n/N = 27/43)
Yes (n/N = 19/27) Yes (n/N = 339/368)
Yes (n/N = 368/368)
No (n/N = 6/224)
No (n/N = 43/763)
Yes (n/N = 148/152) No (n/N = 4/152)


































FIGURE 7 Delivery of consent procedures for patients randomised to the permissive hypotension group. Reproduced
with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.
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Yes (n/N = 769/1143) No (n/N = 374/1143)
Yes (n/N = 736/769)
Yes (n/N = 221/227)
Yes (n/N = 227/736) No (n/N = 509/736) No (n/N = 18/33)
No (n/N = 27/374)No (n/N = 4/15)
Yes (n/N = 15/33)
Yes (n/N = 11/15) Yes (n/N = 347/374)
Yes (n/N = 374/374)
No (n/N = 6/227)
No (n/N = 33/769)
Yes (n/N = 153/157) No (n/N = 4/157)


































FIGURE 8 Delivery of consent procedures for patients randomised to the usual-care group. Reproduced with permission
from Lamontagne et al.59 Copyright © 2020 American Medical Association.
TABLE 7 Baseline characteristics
Characteristic
Permissive hypotension
(N= 1283a) Usual care (N= 1300a)
Age (years), mean (SD) 75.3 (6.6) 75.2 (6.9)
Sex, n (%)
Male 696 (57.2) 692 (55.9)
Female 520 (42.8) 547 (44.1)
Comorbidity, n/N (%)
Chronic hypertension 590/1283 (46.0) 597/1299 (46.0)
Atherosclerotic disease 187/1283 (14.6) 189/1299 (14.5)
Chronic heart failure 143/1283 (11.1) 143/1298 (11.0)
Chronic renal replacement therapy at ICU admission 16/1204 (1.3) 18/1224 (1.5)
Dependency prior to acute hospital admission, n (%)
Able to live without assistance in daily activities 794 (65.6) 850 (69.1)
Minor/major assistance with daily activities 409 (33.8) 375 (30.5)
Total assistance with all daily activities 8 (0.7) 5 (0.4)
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usual care, n = 1100 (86.3%)]. Randomisation did not influence vasopressor choice. Noradrenaline was
most commonly administered (received by around 80% in each group). Just over 30% of patients in each
group received metaraminol and just under 10% received vasopressin (Table 8).
The difference in vasopressor exposure was due to permissive hypotension leading to a change in
clinical management of vasopressors compared with usual care. This was observed immediately post
randomisation, with permissive hypotension leading to lower vasopressor dose rates and MAPs by the
end of the first 24 hours post randomisation (Figure 10), and carried on throughout the first episode of
vasopressors, with clinical teams actively reducing vasopressor doses (Figure 11).
TABLE 7 Baseline characteristics (continued )
Characteristic
Permissive hypotension
(N= 1283a) Usual care (N= 1300a)
Location prior to admission to critical care and urgency of surgery, n (%)
Emergency department/not in hospital 432 (35.4) 420 (33.9)
Theatre: elective/scheduled surgery 53 (4.3) 60 (4.8)
Theatre: emergency/urgent surgery 259 (21.2) 264 (21.3)
Other critical care unit 14 (1.1) 22 (1.8)
Ward or intermediate care area 461 (37.8) 473 (38.2)
APACHE II score, mean (SD) 20.9 (6.5) 20.6 (6.1)
ICNARC physiology score, mean (SD) 23.9 (8.8) 23.5 (8.8)
ICNARCH–2015 predicted risk of death, median (IQR) 0.33 (0.15–0.60) 0.32 (0.14–0.61)
Sepsis-3, n (%)
No sepsis 263 (21.6) 275 (22.2)
Sepsis (not in shock) 364 (29.9) 369 (29.8)
Septic shock 589 (48.4) 595 (48.0)
MAP at randomisation (mmHg), mean (SD) 69.9 (10.1) 71.1 (11.5)
Vasopressor infusions received at time of randomisation,b n (%)
Nonec 15 (1.2) 25 (2.0)
dNoradrenaline equivalent < 0.1 µg/kg/minute 153 (12.1) 155 (12.1)
Noradrenaline equivalent ≥ 0.1 µg/kg/minute 676 (53.4) 677 (52.9)
Metaraminol 406 (32.1) 409 (32.0)
Other/combination 43 (3.4) 34 (2.7)
Duration of vasopressor infusion prior to randomisation
(minutes), median (IQR)
186 (102–277) 186 (104–284)
a Includes all randomised patients, excluding 15 patients who requested all data to be removed (see Consent).
b Noradrenaline-equivalent doses were calculated according to the method described in Khanna et al.45 (see Table 3
for more details).
c Patients in this category were eligible for recruitment prior to version 2.0 of the protocol (29 November 2017) if a
decision had been taken to start vasopressors or if they had received vasopressors in the form of metaraminol or
terlipressin boluses. Version 2.0 of the protocol specified that patients were required to have been started on a
vasopressor infusion for at least 1 hour prior to randomisation.
d In this category, 118 patients in each group received noradrenaline at a dose of < 0.1 µg/kg/minute and were eligible
for recruitment prior to version 2.0 of the protocol (29 November 2017). Version 2.0 of the protocol specified that
patients receiving norepinphrine must fulfil a minimum dose of 0.1 µg/kg/minute at the time of randomisation.
A minimum dose was not required for other vasopressors.
Reproduced with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.
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FIGURE 9 Time to discontinuation of vasopressors. Reports the time (hours) to discontinuation of vasopressors from
randomisation. Reproduced with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.








Total duration of vasopressors (hours)
Median (IQR) 33.0 (15.0–56.0) 38.0 (19.0–67.0)
Mean (SD) 46.0 (52.4) 55.9 (60.8) –9.9 (–14.3 to –5.5)
Total dose of vasopressors (mg)
Noradrenaline equivalents n= 1008 n= 1021
Median (IQR)b 17.7 (5.8–47.2) 26.4 (8.9–65.6)
Mean (SD)c 31.5 (57.4) 44.3 (76.4) –12.8 (–18.0 to –7.6)
Metaraminol n= 395 n= 420
Median (IQR)b 22.0 (9.3–60.0) 35.0 (12.7–79.8)
Mean (SD)c 15.7 (51.2) 19.8 (53.2) –4.1 (–8.3 to –0.0)
Terlipressin n= 10 n= 14
Median (IQR)b 2.5 (1.0–10.8) 3.3 (1.0–6.0)
Mean (SD)c 0.1 (1.0) 0.1 (0.7) 0.0 (0.0 to 0.1)
Mean dose rate of vasopressorsb
Noradrenaline equivalents
(µg/kg/minute)
n= 1008 n= 1021
Median (IQR) 0.12 (0.06–0.23) 0.15 (0.08–0.26)
Mean (SD) 0.21 (0.45) 0.22 (0.24) –0.02 (–0.05 to 0.02)
Metaraminol (mg/hour) n= 385 n= 408
Median (IQR) 2.35 (1.44–4.25) 2.83 (1.95–4.88)
Mean (SD) 3.41 (2.99) 3.81 (3.04) –0.40 (–0.80 to 0.01)
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Following randomisation and during the first episode of vasopressors, mean and peak MAP values were
lower in the permissive hypotension group than in the usual-care group (Figure 12 and Tables 9–11).
For permissive hypotension, patients had a mean MAP of 67.6 mmHg (SD 5.2 mmHg) while receiving
vasopressors compared with 72.9 mmHg (SD 5.8 mmHg) for usual care. Even though a lower MAP was
targeted, this did not lead to a clinically significant increase in duration with a MAP of < 60 mmHg
(see Tables 10 and 11).








Highest dose rate of vasopressorsb
Noradrenaline equivalents
(µg/kg/minute)
n= 1008 n= 1021
Median (IQR) 0.26 (0.13–0.57) 0.32 (0.16–0.63)
Mean (SD) 0.44 (0.74) 0.47 (0.49) –0.03 (–0.09 to 0.02)
Metaraminol (mg/hour) n= 385 n= 408
Median (IQR) 4.00 (3.00–6.50) 5.00 (3.50–7.00)
Mean (SD) 5.39 (3.96) 5.73 (3.60) –0.34 (–0.88 to 0.20)
Total number of episodes of vasopressor treatment at critical care discharge, n (%)
One 1094 (86.8) 1100 (86.3)
Two 113 (9.0) 115 (9.0)
Three 34 (2.7) 30 (2.4)
Four 12 (1.0) 14 (1.1)
Five 2 (0.2) 7 (0.5)
Six 4 (0.3) 3 (0.2)
Total number of calendar days on vasopressors at critical care discharge, n (%)
One or two 628 (49.8) 544 (42.7)
Three or four 381 (30.2) 414 (32.5)
Five or six 111 (8.8) 138 (10.8)
Seven or more 139 (11.0) 173 (13.6)
Vasopressors received, n (%)
Noradrenaline 992 (78.7) 997 (78.1)
Adrenaline 40 (3.2) 42 (3.3)
Dopamine 1 (0.1) 2 (0.2)
Phenylephrine 32 (2.5) 33 (2.6)
Vasopressin 123 (9.8) 126 (9.9)
Metaraminol 395 (31.3) 418 (32.8)
Terlipressin 10 (0.8) 14 (1.1)
a Total number of patients with treatment data recorded until completion of the first treatment episode.
b Among patients receiving the vasopressor(s).
c Among all patients.
Reproduced with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.
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FIGURE 10 Dose/rate of noradrenaline equivalents and MAP change post randomisation. Values reported are the mean
noradrenaline dose/rate and mean MAPs for the first 24 hours post randomisation, by hour. Patients are included while
receiving a noradrenaline-equivalent vasopressor on the given hour. Points are labelled by hours post randomisation,
with the last available pre-randomisation value (baseline) labelled as hour 0. Reproduced with permission from






























MAP > 75 mmHg, dose not reduced
MAP 65–75 mmHg, dose not reduced
MAP > 65 mmHg, dose reduced
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MAP > 75 mmHg, dose not reduced
MAP 65–75 mmHg, dose not reduced
MAP > 65 mmHg, dose reduced
MAP 60–65 mmHg
MAP < 60 mmHg
FIGURE 11 Treatment hours: MAP and vasopressor dose reductions. (a) Mean hours of treatment; and (b) percentage
of all treatment hours by randomised group. Reproduced with permission from Lamontagne et al.59 Copyright © 2020
American Medical Association.
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FIGURE 12 Mean arterial pressure values days 1–7 post randomisation. These box and whisker plots summarise the median of the (a) mean MAPs; and (b) peak (highest) MAPs for
values recorded hourly during patient’s first episode of vasopressors for days 1–7 post randomisation. Numbers at the foot of each box represent the denominators for the numbers for
that box (i.e. the number of patients receiving vasopressors on the given day). Median and quartiles (boxes) are shown with upper and lower adjacent values of median ± 1.5 × IQR

















































































































































































































































































































































TABLE 11 Percentage of hours on vasopressors at different MAP ranges during the first episode of vasopressors
Percentage of hours on vasopressors Permissive hypotension (n= 1261a) Usual care (n= 1276a)
Time on vasopressors with recorded MAP of < 60 mmHg (percentage of all treatment hours)
Mean (SD) 8.8 (16.0) 4.9 (10.4)
Time on vasopressors with recorded MAP of between 60 and 65mmHg (percentage of all treatment hours)
Mean (SD) 41.1 (51.5) 16.1 (24.3)
Time on vasopressors with recorded MAP of between 65 and 70mmHg (percentage of all treatment hours)
Mean (SD) 22.9 (29.8) 22.3 (27.1)
Time on vasopressors with recorded MAP of > 70 mmHg (percentage of all treatment hours)
Mean (SD) 27.3 (44.7) 56.6 (67.6)
a Total number of patients with treatment data recorded until completion of the first treatment episode.
TABLE 9 Mean and peak MAPs during first episode of vasopressors








Mean MAP while receiving vasopressors (mmHg)
Median (IQR) 66.7 (64.5–69.8) 72.6 (69.4–76.5)
Mean (SD) 67.6 (5.2) 72.9 (5.8) –5.3 (–5.8 to –4.9)
Peak MAP while receiving vasopressors (mmHg)
Median (IQR) 83.0 (75.0–92.0) 92.0 (85.0–100.0)
Mean (SD) 84.9 (14.9) 93.2 (13.8) –8.4 (–9.5 to –7.2)
a Total number of patients with treatment and MAP data recorded until completion of the first treatment episode.
Reproduced with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.
TABLE 10 Time on vasopressors at different MAP ranges during the first episode of vasopressors
Time (hours) on vasopressors Permissive hypotension (n= 1261a) Usual care (n= 1276a)
Time (hours) on vasopressors with recorded MAP of < 60 mmHg
Mean (SD) 3.6 (6.5) 2.5 (5.3)
Time (hours) on vasopressors with recorded MAP of between 60 and 65mmHg
Mean (SD) 16.8 (21.0) 8.2 (12.4)
Time (hours) on vasopressors with recorded MAP between 65 and 70mmHg
Mean (SD) 9.3 (12.2) 11.4 (13.9)
Time (hours) on vasopressors with recorded MAP of > 70 mmHg
Mean (SD) 11.2 (18.3) 28.9 (34.5)
a Total number of patients with treatment data recorded until completion of the first treatment episode.
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Adherence to permissive hypotension
Periods of non-adherence to permissive hypotension were observed in 153 (11.9%) patients, equating
to 6% of the total time patients in the permissive hypotension group received vasopressors (Table 12).
The main reason for not reducing or discontinuing vasopressors during a 3-hour period of a MAP of
> 65 mmHg was staff/logistical issues (n = 102). This included lack of trial awareness (n = 54), focus on
other clinical priorities (n = 42) and no reason documented (n = 6). In 51 of the patients with periods of
non-adherence, patient concerns were the documented reason. These concerns included renal (n = 36),
cardiac (n = 4), history of chronic hypertension (n = 2), gastrointestinal (n = 2) and other (n = 7).
Co-interventions
There was no clinically important difference in fluid balance, urine output or use of pure inotropes
during the first episode of vasopressors. A slightly higher number of patients in the usual-care group
(n = 432, 33.9%) received corticosteroids than in the permissive hypotension group (n = 398, 31.6%)
(Table 13 and Figure 13).
TABLE 12 Adherence to permissive hypotension
Failure to discontinue vasopressors or reduce the dose/rate once MAP was > 65mmHg
Permissive hypotension
(n= 1283a)
Number of potential periods of non-adherence 456
Number of periods determined not to be non-adherence 303
Number (%) of patients experiencing at least one period of non-adherence 153 (11.9)
Total (%) hours of non-adherence 3519 (6.0)
a Includes all randomised patients in the permissive hypotension group, excluding eight patients who did not consent
to the trial and who refused permission for use of data.
Note
A potential period of non-adherence was defined as 3 consecutive hours with MAP > 65mmHg and with no recorded
dose reduction.
TABLE 13 Fluid balance, urine output and co-interventions during first episode of vasopressors
Co-intervention Permissive hypotension Usual care
Fluid balance at end of first episode of vasopressors (ml)
n 1247 1268
Median (IQR) 3041 (1307–5744) 2904 (1071–5789)
Mean (SD) 3993 (4238) 3976 (5202)
Mean urine output during first episode of vasopressors (ml/kg/hour)
n 1246 1266
Median (IQR) 0.5 (0.2–0.8) 0.6 (0.2–0.9)
Mean (SD) 0.6 (0.5) 0.6 (0.6)
Co-intervention received during first episode of vasopressors
n 1261 1276
Corticosteroids, n (%) 398 (31.6) 432 (33.9)
Inotropes, n (%) 268 (21.3) 256 (20.1)
Reproduced with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.
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FIGURE 13 Fluid balance and urine output days 1–7 post randomisation. These box and whisker plots summarise the median (a) daily fluid balance; and (b) daily urine output for values
recorded during patient’s first episode of vasopressors for days 1–7 post randomisation. Numbers at the foot of each box represent the denominators for the numbers for that box
(i.e. the number of patients receiving vasopressors on the given day). Median and quartiles (boxes) are shown with upper and lower adjacent values of median ± 1.5 × IQR (whiskers).






























At 90 days following randomisation, 500 (41.0%) patients randomised to permissive hypotension had
died compared with 544 (43.8%) patients randomised to usual care, corresponding to an absolute
risk reduction of –2.85 (95% CI –6.75 to 1.05; p = 0.154) (Table 14). When adjusted for prespecified
baseline variables, the odds ratio for 90-day mortality was 0.82 (95% CI 0.68 to 0.98) compared with
an unadjusted odds ratio of 0.89 (95% CI 0.76 to 1.04) (see Table 14).
Secondary outcomes
All secondary outcomes were similar between the groups (see Table 14). Mortality at critical care unit
discharge was 29.9% in the permissive hypotension group compared with 30.7% in the usual-care group.
This increased by acute hospital discharge to 39.3% and 41.5%, respectively. There was no significant








90-day mortality, n/N (%) 500/1221 (41.0) 544/1242 (43.8) –2.85 (–6.75 to 1.05)a 0.154
0.93 (0.85 to 1.03)b
0.89 (0.76 to 1.04)c
0.82 (0.68 to 0.98)d
Secondary outcomes
Mortality at discharge from the
critical care unit, n/N (%)
362/1212 (29.9) 380/1237 (30.7) –0.85 (–4.49 to 2.79)a
0.97 (0.86 to 1.10)b
0.96 (0.81 to 1.14)c
0.90 (0.73 to 1.10)d
Mortality at discharge from
acute hospital, n/N (%)
484/1232 (39.3) 519/1250 (41.5) –2.23 (–6.09 to 1.63)a
0.95 (0.86 to 1.04)b
0.91 (0.78 to 1.07)c
0.86 (0.71 to 1.03)d
Advanced respiratory support
Receipt, n/N (%) 708/1218 (58.1) 691/1239 (55.8)
Duration (days), median
(IQR)e
4.0 (2.0–10.0) 4.0 (2.0–10.0)
Duration (days), mean (SD)f 4.5 (8.3) 4.8 (10.0) –0.3 (–1.1 to 0.4)g
–0.3 (–1.0 to 0.4)h
Days alive and free of advanced
respiratory support to day 28,
mean (SD)
15.7 (12.8) 15.1 (13.0) 0.6 (–0.4 to 1.7)g
0.9 (0.0 to 1.8)h
continued
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Receipt, n/N (%) 302/1218 (24.8) 306/1239 (24.7)
Duration (days), median
(IQR)e
4.0 (2.0–7.0) 4.0 (2.0–8.0)
Duration (days), mean (SD)f 1.4 (3.6) 1.5 (4.1) –0.1 (–0.4 to 0.2)g
–0.2 (–0.4 to 0.1)h
Days alive and free of
renal support to day 28,
mean (SD)
17.4 (13.2) 16.7 (13.4) 0.6 (–0.4 to 1.7)g
0.9 (0.0 to 1.9)h
Duration of critical care unit stay (days), median (IQR)
Survivors 5.2 (2.9–10.5) 5.4 (3.0–9.9)
Non-survivors 3.2 (0.9–8.1) 2.7 (0.9–8.7)
Duration of acute hospital stay (days), median (IQR)
Survivors 18.0 (10.0–34.0) 18.0 (10.0–36.0)
Non-survivors 6.0 (1.0–15.0) 5.0 (1.0–14.5)
Cognitive decline (IQCODE score) among survivors, non-missing outcomes only, mean (SD)
At 90 days 2.96 (0.66) 2.97 (0.66) –0.01 (–0.09 to 0.07)g
–0.01 (–0.09 to 0.07)h
At 1 year 2.95 (0.72) 2.81 (0.81) 0.14 (–0.00 to 0.28)g
0.12 (–0.01 to 0.25)h
Cognitive decline (IQCODE score) among survivors, non-missing outcomes, median (IQR)
At 90 days 3.00 (3.00–3.13) 3.00 (3.00–3.19)
At 1 year 3.00 (3.00–3.19) 3.00 (2.81–3.13)
Cognitive decline (IQCODE score) among survivors, missing outcomes imputed, mean (SD)
At 90 days 2.97 (0.72) 2.98 (0.76) –0.01 (–0.09 to 0.07)g
–0.01 (–0.09 to 0.07)h
At 1 year 2.93 (0.81) 2.80 (0.96) 0.13 (–0.00 to 0.25)g
0.12 (–0.00 to 0.25)h
a Absolute risk reduction.
b Relative risk.
c Unadjusted odds ratio.
d Adjusted odds ratio.
e Among patients receiving the organ support.
f Among all patients.
g Unadjusted difference in means (bootstrapped).
h Adjusted difference in means.
Reproduced with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.
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Receipt and duration of advanced respiratory and renal support were similar between the groups.
In the permissive hypotension group, 24.8% of patients received renal support for a median of 4.0
(IQR 2.0–7.0) days, compared with 24.7% of patients for a median duration of 4.0 (IQR 2.0–8.0) days
in the usual-care group. Among patients in the permissive hypotension group who survived to critical
care discharge, median length of stay was 5.2 (IQR 2.9–10.5) days, compared with 5.4 (IQR 3.0–9.9) days
in the usual-care group.With respect to acute hospital length of stay, survivors in both groups spent
a median of 18 days in hospital. Cognitive function at 90 days and 1 year was similar between the groups
(see Table 14).
All randomised patients are included when calculating survival, excluding 15 patients who did not
consent to the trial and who refused permission for use of personal data (permissive hypotension,
n = 8; usual care, n = 7). Other surviving patients were censored at last known date alive (where trial
consent was obtained) or at date of withdrawal/refusal of consent (where trial consent was not obtained).
Serious adverse events
A similar number of patients in each group experienced one or more SAEs [79 (6.2%) patients in the
permissive hypotension group and 75 (5.8%) patients in the usual-care group; p = 0.68] (Table 15).
Of the prespecified expected adverse events, in both groups, the most commonly reported SAE was
severe acute renal failure (defined in accordance with the Kidney Disease: Improving Global Outcomes66
stage 3 criteria), which was reported numerically more frequently in the permissive hypotension group.
The numbers of reported myocardial injury and mesenteric ischaemia SAEs were small, although
numerically more frequent in the usual-care group. Numbers of other SAEs that were not prespecified
in the protocol were low, with cardiac arrests reported as a SAE in a similar proportion of patients in
each group (i.e. < 1% of patients).
Subgroup analyses
For the majority of subgroups (i.e. age, chronic heart failure, atherosclerotic disease, predicted risk of
death, sepsis status and vasopressor dose), there was no evidence of heterogeneity of treatment effect
(Table 16 and Figure 15). Within the chronic hypertension subgroup, a mortality rate of 38.2% in the
permissive hypotension group and 44.3% in usual-care group for patients with chronic hypertension
(adjusted odds ratio 0.67, 95% CI 0.51 to 0.88), compared with 43.3% and 43.4%, respectively, in
patients without chronic hypertension (adjusted odds ratio 0.97, 95% CI 0.76 to 1.24), was observed









































FIGURE 14 Kaplan–Meier survival curves. Reproduced with permission from Lamontagne et al.59 Copyright © 2020
American Medical Association.
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TABLE 15 Serious adverse events
SAE
Permissive hypotension
(N= 1283a), n (%)b
Usual care
(N= 1300a), n (%)b
Any SAE 79 (6.2) 75 (5.8)
Specified SAEs
Supraventricular cardiac arrhythmia 12 (0.9) 13 (1.0)
Ventricular cardiac arrhythmia 12 (0.9) 5 (0.4)
Myocardial injury 8 (0.6) 12 (0.9)
Extremity necrosis 4 (0.3) 3 (0.2)
Mesenteric ischaemia 8 (0.6) 12 (0.9)
Severe acute renal failure 41 (3.2) 33 (2.5)
Other SAEs
Cardiac arrest 11 (0.9) 10 (0.8)
Stroke 3 (0.2) 5 (0.4)
Acute ischaemic liver failure 1 (0.1) 0 (0.0)
Major haemorrhage 1 (0.1) 0 (0.0)
Massive bleed (abdominal) 1 (0.1) 0 (0.0)
Multiple kidney infarctions 0 (0.0) 1 (0.1)
Pneumobilia 0 (0.0) 1 (0.1)
Pneumothorax 1 (0.1) 0 (0.0)
a Includes all randomised patients, excluding 15 patients who did not consent to the trial and who refused permission
for use of data (permissive hypotension, n = 8; usual care, n= 7).
b Values are number and percentage. Some patients experienced more than one SAE. SAEs were monitored and
recorded between randomisation and critical care unit discharge.
Reproduced with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.
TABLE 16 Subgroup analysis of primary outcome
Subgroup





Age (quintiles) (years) 0.107b
65–69c 108/289 (37.4) 124/304 (40.8) 0.87 (0.60 to 1.27)
69–72 62/194 (32.0) 70/224 (31.3) 1.13 (0.71 to 1.81)
72–77 127/304 (41.8) 121/274 (44.2) 0.76 (0.52 to 1.11)
77–82 115/243 (47.3) 111/219 (50.7) 0.72 (0.48 to 1.10)
> 82 88/191 (46.1) 118/221 (53.4) 0.66 (0.43 to 1.01)
Chronic hypertension 0.047
No 286/661 (43.3) 291/671 (43.4) 0.97 (0.76 to 1.24)
Yes 214/560 (38.2) 253/571 (44.3) 0.67 (0.51 to 0.88)
Chronic heart failure 0.811
No 431/1085 (39.7) 467/1104 (42.3) 0.82 (0.68 to 1.00)
Yes 69/136 (50.7) 77/137 (56.2) 0.77 (0.45 to 1.31)
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Secondary analyses of the primary outcome
Secondary and sensitivity analyses of the primary outcome, through adherence-adjusted analysis,
best- and worst-case sensitivity analyses and including only patients eligible from version 2.0 of the
protocol, did not alter the interpretation of the primary results (Table 17).
Analysis by chronic hypertension status
In a prespecified analysis by chronic hypertension status, the mortality secondary outcomes were
similar to those observed in the chronic hypertension subgroup analysis of the primary outcome.
For patients with chronic hypertension, critical care unit and acute mortality was 26.6% and 37.2%,
respectively, in the permissive hypotension group, compared with 29.5% and 42.8%, respectively, in the
usual-care group. Other secondary outcomes were similar by chronic hypertension status (Table 18).
TABLE 16 Subgroup analysis of primary outcome (continued )
Subgroup






No 424/1047 (40.5) 458/1062 (43.1) 0.79 (0.65 to 0.96)
Yes 76/174 (43.7) 86/180 (47.8) 1.00 (0.62 to 1.60)
Predicted risk of death (quintiles) 0.691d
< 0.11 33/238 (13.9) 34/252 (13.5) 0.99 (0.59 to 1.68)
0.11–0.24 55/240 (22.9) 63/250 (25.2) 0.86 (0.56 to 1.31)
0.24–0.42 79/234 (33.8) 114/257 (44.4) 0.63 (0.43 to 0.92)
0.42–0.68 135/259 (52.1) 124/231 (53.7) 0.99 (0.69 to 1.43)
> 0.68 195/242 (80.6) 209/248 (84.3) 0.75 (0.47 to 1.21)
Sepsis-3 category 0.062
No sepsis 124/263 (47.1) 117/275 (42.5) 1.15 (0.77 to 1.71)
Sepsis (not in shock) 112/364 (30.8) 138/368 (37.5) 0.62 (0.44 to 0.86)
Septic shock 262/589 (44.5) 289/595 (48.6) 0.83 (0.64 to 1.08)
Vasopressor infusions received at randomisation 0.363
None 7/15 (46.7) 9/22 (40.9) 1.61 (0.35 to 7.54)
Noradrenaline < 0.1 µg/kg/minute 44/142 (31.0) 57/148 (38.5) 0.63 (0.36 to 1.09)
Noradrenaline ≥ 0.1 µg/kg/minute 308/648 (47.5) 324/653 (49.6) 0.88 (0.69 to 1.13)
Metaraminol 131/385 (34.0) 139/387 (35.9) 0.80 (0.57 to 1.11)
Other/combination 5/15 (33.3) 8/13 (61.5) 0.20 (0.03 to 1.25)
a p-value for test of interaction in adjusted multilevel logistic regression model.
b Test of continuous linear interaction with age: adjusted odds ratio 0.82 (95% CI 0.69 to 0.99) at age 75 years
(mean value); interaction odds ratio 0.90 (95% CI 0.78 to 1.02) per 5-year increase in age.
c Three patients in the usual-care group were identified after randomisation to be aged < 65 years.
d Test of continuous linear interaction with predicted log-odds of acute hospital mortality: adjusted odds ratio 0.82
(95% CI 0.68 to 0.99) at predicted log-odds of –0.64 (mean value) (predicted risk of 35%); interaction odds ratio
0.97 (95% CI 0.84 to 1.12) per increase of 1 in predicted log-odds.
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Norepinephrine < 0.1 μg/kg/minute




















































0.87 (0.60 to 1.27)
1.13 (0.71 to 1.81)
0.76 (0.52 to 1.11)
0.72 (0.48 to 1.10)
0.66 (0.43 to 1.01)
0.97 (0.76 to 1.24)
0.67 (0.51 to 0.88)
0.82 (0.68 to 1.00)
0.77 (0.45 to 1.31)
0.79 (0.65 to 0.96)
1.00 (0.62 to 1.60)
0.99 (0.59 to 1.68)
0.86 (0.56 to 1.31)
0.63 (0.43 to 0.92)
0.99 (0.69 to 1.43)
0.75 (0.47 to 1.21)
1.15 (0.77 to 1.71)
0.62 (0.44 to 0.86)
0.83 (0.64 to 1.08)
1.61 (0.35 to 7.54)
0.63 (0.36 to 1.09)
0.88 (0.69 to 1.13)
0.80 (0.57 to 1.11)
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n/N (%) Effect estimate (95% CI)
90-day mortality, non-missing data only 500/1221 (41.0) 544/1242 (43.8) –3.24% (–7.68% to 1.20%)a
90-day mortality, all missing intervention
patients assumed alive, all missing control
patients assumed dead (best-case scenario)
500/1283 (39.0) 602/1300 (46.3) –7.34% (–11.14% to –3.53%)b
0.84 (0.77 to 0.92)c
0.74 (0.63 to 0.87)d
90-day mortality, all missing intervention
patients assumed dead, all missing control
patients assumed alive (worst-case scenario)
562/1283 (43.8) 544/1300 (41.8) 1.96% (–1.86% to 5.77%)b
1.05 (0.96 to 1.14)c
1.08 (0.93 to 1.27)d
90-day mortality, patients eligible under
protocol version 2.0 only (started vasopressors
1–6 hours prior to randomisation, with
noradrenaline at least 0.1 µg/kg/minute)
408/961 (42.5) 435/965 (45.1) –2.62% (–7.05% to 1.81%)b
0.94 (0.85 to 1.04)c
0.90 (0.75 to 1.08)d
0.81 (0.66 to 1.00)e
a Adjusted odds ratio from complier-average causal effect analysis (estimated effect among patients with no recorded
episodes of non-adherence).
b Absolute risk reduction.
c Relative risk.
d Unadjusted odds ratio.
e Adjusted odds ratio (adjusted for age, sex, comorbidities, prior dependency, vasopressor infusions received at
randomisation, duration of vasopressor infusion prior to randomisation, location prior to admission to critical care/
urgency of surgery, ICNARC physiology score and Sepsis-3 category).
Reproduced with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.






Mortality at discharge from the critical care unit, n/N (%)
No chronic hypertension 214/655 (32.7) 213/670 (31.8) 1.05 (0.76 to 1.34)a
Chronic hypertension 148/557 (26.6) 167/567 (29.5) 0.74 (0.51 to 0.97)a
Mortality at discharge from acute hospital, n/N (%)
No chronic hypertension 274/667 (41.1) 274/678 (40.4) 1.03 (0.77 to 1.29)a
Chronic hypertension 210/565 (37.2) 245/572 (42.8) 0.69 (0.50 to 0.88)a
Advanced respiratory support: no chronic hypertension
Receipt, n/N (%) 373/660 (56.5) 372/671 (55.4)
Duration (days), median (IQR)b 3.0 (2.0–9.0) 4.0 (2.0–10.0)
Duration (days), mean (SD)c 4.4 (8.8) 4.7 (9.1) –0.1 (–1.0 to 0.9)d
Days alive and free of advanced respiratory
support to day 28, mean (SD)
15.2 (13.1) 15.2 (13.0) 0.1 (–1.1 to 1.2)d
continued
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Advanced respiratory support: chronic hypertension
Receipt, n/N (%) 335/558 (60.0) 319/568 (56.2)
Duration (days), median (IQR)b 4.0 (2.0–10.0) 4.0 (2.0–11.0)
Duration (days), mean (SD)c 4.6 (7.6) 4.9 (11.0) –0.6 (–1.6 to 0.4)d
Days alive and free of advanced respiratory
support to day 28, mean (SD)
16.3 (12.6) 14.9 (12.9) 1.9 (0.6 to 3.2)d
Renal support: no chronic hypertension
Receipt, n/N (%) 144/660 (21.8) 166/671 (24.7)
Duration (days), median (IQR)b 4.0 (2.0–7.0) 4.0 (2.0–8.0)
Duration (days), mean (SD)c 1.2 (3.4) 1.5 (4.1) –0.3 (–0.7 to 0.1)d
Days alive and free of renal support to
day 28, mean (SD)
16.9 (13.4) 16.9 (13.4) 0.1 (–1.1 to 1.4)d
Renal support: chronic hypertension
Receipt, n/N (%) 158/558 (28.3) 140/568 (24.6)
Duration (days), median (IQR)b 4.0 (2.0–8.0) 4.0 (2.0–7.0)
Duration (days), mean (SD)c 1.7 (3.9) 1.6 (4.2) 0.0 (–0.4 to 0.5)d
Days alive and free of renal support to day 28,
mean (SD)
18.0 (12.9) 16.6 (13.3) 1.9 (0.5 to 3.2)d
Duration of ICU stay (days): no chronic hypertension, median (IQR)
Survivors 4.8 (2.6–9.3) 5.2 (2.9–9.2)
Non-survivors 3.8 (1.2–8.4) 3.8 (1.2–8.9)
Duration of ICU stay (days): chronic hypertension, median (IQR)
Survivors 5.1 (3.0–10.6) 5.4 (2.8–9.9)
Non-survivors 4.4 (1.6–10.8) 4.2 (1.4–9.9)
Duration of acute hospital stay (days): no chronic hypertension, median (IQR)
Survivors 16.5 (9.0–33.0) 19.0 (10.0–36.0)
Non-survivors 5.0 (1.0–13.0) 5.0 (1.0–12.0)
Duration of acute hospital stay (days): chronic hypertension, median (IQR)
Survivors 18.0 (11.0–36.0) 17.0 (10.0–37.5)
Non-survivors 7.0 (2.0–18.0) 6.0 (1.0–18.0)
a Adjusted odds ratio (adjusted for age, sex, comorbidities, prior dependency, vasopressor infusions received at
randomisation, duration of vasopressor infusion prior to randomisation, location prior to admission to critical care/
urgency of surgery, ICNARC physiology score and Sepsis-3 category).
b Duration among those receiving the support.
c Duration among all randomised patients.
d Adjusted difference in means (adjusted for age, sex, comorbidities, prior dependency, vasopressor infusions received
at randomisation, duration of vasopressor infusion prior to randomisation, location prior to admission to critical
care/urgency of surgery, ICNARC physiology score and Sepsis-3 category).
Reproduced with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.
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Cost-effectiveness
Primary economic outcome at 90 days
Resource use and costs at 90 days
Table 19 shows the resource use up to 90 days post randomisation. Mean total dose of noradrenaline-
equivalent vasopressors was 30.3 mg in the permissive hypotension group and 43.2 mg in the usual-care
group, and of metaraminol was 15.5 mg in the permissive hypotension group and 19.7 mg in the
usual-care group. For the index hospital episode, the mean critical care length of stay was lower in the
permissive hypotension group than in the usual-care group, but mean length of stay in general medical
wards was similar. Mean length of stay in critical care and general medical wards from readmissions
was low and similar between groups. The mean total length of stay up to 90 days in the permissive
hypotension and usual-care groups were 20.8 days and 21.0 days, respectively.
Table 20 summarises resource use reported from responses to the health services questionnaire.
The average number of inpatient days reported from admissions other than those to critical care was
higher in the permissive hypotension group than in the usual-care group. Patients in the usual-care
group had higher average numbers of outpatient visits and contacts with a GP, nurses, health visitors,
occupational therapists and physiotherapists than patients in the permissive hypotension group.
All other community care contacts up to 90 days were low and similar between the groups.
Table 21 reports total costs per patient up to 90 days. Intervention (vasopressor) costs per patient
were lower for the permissive hypotension group (£83) than for the usual-care group (£104). Index
hospital stay accounts for a major share of total costs for both randomised groups. The mean total cost
per patient was slightly lower in the permissive hypotension group (£19,034) than in the usual-care
group (£19,413).
TABLE 19 Resource use up to 90 days post randomisation
Resource use
Permissive hypotension
(N= 1218), mean (SD)
Usual care (N= 1238),
mean (SD)
Intervention
Noradrenaline dose infused (mg) 30.27 (54.89) 43.17 (74.18)
Dopamine dose infused (mg) 0.44 (15.24) 1.78 (44.58)
Phenylephrine dose infused (mg) 0.29 (3.03) 0.66 (7.00)
Terlipressin dose infused (mg) 0.06 (0.98) 0.05 (0.68)
Adrenaline dose infused (mg) 0.48 (4.25) 0.38 (3.65)
Vasopressin (unit) 5.36 (30.37) 5.35 (24.49)
Metaraminol dose infused (mg) 15.50 (51.49) 19.66 (53.38)
Index admission
Days in critical care 8.29 (10.78) 8.57 (11.94)
General medical bed-days 12.32 (17.59) 12.31 (17.24)
Readmissions
Readmissions 15 (1.23) 18 (1.45)
Days in critical care 0.06 (0.74) 0.05 (0.58)
General medical bed-days 0.11 (1.34) 0.12 (1.45)
Total length of stay up to 90 days 20.79 (22.02) 21.04 (22.46)
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Health-related quality of life at 90 days
The health status profiles reported from EQ-5D-5L responses at 90 days are summarised by
randomised group in Table 22. At 90 days, the proportion of patients who reported ‘no problems’ for
each dimension of the EQ-5D-5L (except anxiety/depression) in the permissive hypotension group was
higher than for the usual-care group.




(n= 657), mean (SD)
Usual care (n= 643),
mean (SD)
Inpatient days (general medical) 6.25 (14.95) 5.47 (13.28)
Outpatient visits 2.15 (3.08) 2.22 (3.17)
GP contacts 1.68 (2.66) 1.78 (2.55)
Nurse contacts 2.54 (4.83) 2.68 (5.44)
Health visitor contacts 0.94 (2.75) 1.37 (5.05)
Occupational therapist contacts 0.63 (2.92) 1.00 (4.41)
Speech therapist contacts 0.07 (0.51) 0.08 (0.53)
Physiotherapist contacts 0.60 (1.50) 0.97 (2.77)
Psychiatrist contacts 0.02 (0.20) 0.04 (0.44)
Psychiatric nurse contacts 0.07 (0.58) 0.06 (0.50)
Psychologist contacts 0.03 (0.27) 0.02 (0.18)
Counsellor contacts 0.05 (0.46) 0.02 (0.41)
a Reported for patients who were alive and completed the health services questionnaire at 90 days
post randomisation.
TABLE 21 Costs (GBP) up to 90 days post randomisation
Cost
Permissive hypotension
(n= 1218) (£) Usual care (n= 1238) (£)
Intervention costs 83 (177) 104 (186)
Hospital costs: index admission
Critical care 13,277 (18,909) 13,823 (21,251)
General medical ward 4153 (5927) 4147 (5810)
Hospital costs: readmissiona
Critical care 92 (1186) 67 (895)
General medical 38 (450) 41 (488)
Outpatient and community costsa,b 1392 (3728) 1231 (3512)
Total costs up to 90 daysa,b,c 19,034 (21,433) 19,413 (23,478)
a Following multiple imputation to handle missing resource use data.
b 65 trial and CMP database.
c Health services questionnaire.
Note
All numbers are mean (SD) unless stated otherwise.
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Cost-effectiveness at 90 days (primary outcome)
At 90 days, the average cost and mean EQ-5D-5L index scores were similar between groups (Table 23).
After adjustment for baseline characteristics, the incremental life-years and QALYs were higher in the
permissive hypotension group, with the majority of points (95%) falling on those quadrants on the
cost-effectiveness plane, indicating that permissive hypotension had higher mean QALYs (Figure 16).
Therefore, the INMB for permissive hypotension compared with usual care was positive, but with a
wide CI. At £20,000 per QALY, the INMB was £378 (95% CI −£1347 to £2103). The probability that
permissive hypotension is cost-effective is < 70% at the £20,000–30,000 per QALY threshold (Figure 17).
The cost-effectiveness results were similar across prespecified subgroups (see Figure 18).
TABLE 22 Quality-of-life (EQ-5D-5L) health state profiles at 90 days post randomisation
EQ-5D-5L componenta
Permissive hypotension
(N= 657), n (%)
Usual care
(N= 643), n (%)
Mobility
No problems 141 (21.46) 121 (18.82)
Slight problems 113 (17.20) 110 (17.11)
Moderate problems 136 (20.70) 150 (23.33)
Severe problems 83 (12.63) 60 (9.33)
Extreme problems 42 (6.39) 34 (5.29)
Self-care
No problems 279 (42.47) 261 (40.59)
Slight problems 85 (12.94) 90 (14.00)
Moderate problems 84 (12.79) 78 (12.13)
Severe problems 28 (4.26) 18 (2.80)
Extreme problems 37 (5.63) 26 (4.04)
Usual activities
No problems 127 (19.33) 111 (17.26)
Slight problems 125 (19.03) 117 (18.20)
Moderate problems 117 (17.81) 129 (20.06)
Severe problems 78 (11.87) 56 (8.71)
Extreme problems 67 (10.20) 58 (9.02)
Pain/discomfort
No problems 159 (24.20) 141 (21.93)
Slight problems 152 (23.14) 139 (21.62)
Moderate problems 139 (21.16) 140 (21.77)
Severe problems 53 (8.07) 48 (7.47)
Extreme problems 9 (1.37) 8 (1.24)
Anxiety/depression
No problems 260 (39.57) 243 (37.79)
Slight problems 148 (22.53) 136 (21.15)
Moderate problems 81 (12.33) 70 (10.89)
Severe problems 17 (2.59) 19 (2.95)
Extreme problems 6 (0.91) 9 (1.40)
a Reported for patients who were alive and completed the health services questionnaire at 90 days post randomisation.
Reproduced with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.
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TABLE 23 Cost-effectiveness primary outcome at 90 days
Outcome
Permissive hypotension
(n= 1283), mean (SD)
Usual care (n= 1300),
mean (SD) Effect estimate (95% CI)
Costs (£) 19,034 (21,433) 19,413 (23,478) –311 (–2042 to 1420)
EQ-5D-5L (survivors) 0.677 (0.274) 0.683 (0.272) –0.0003 (–0.031 to 0.031)
Life-years 0.160 (0.108) 0.155 (0.109) 0.008 (0.000 to 0.015)
QALYs 0.050 (0.049) 0.048 (0.049) 0.003 (–0.0004 to 0.007)
INMB (£)a 378 (–1347 to 2103)a
a The INMB is calculated in accordance with NICE methods guidance, by multiplying the mean QALY gain (or loss) by
£20,000 and subtracting from this the incremental cost.
Notes
All results reported after applying multiple imputation to handle missing data. The incremental effects are reported
after applying case-mix adjustment.
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FIGURE 16 Uncertainty in the mean costs (£) and QALY differences and their distribution for intervention vs. usual care
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FIGURE 17 Cost-effectiveness acceptability curve at 90 days. Reports the probability that permissive hypotension is
cost-effective at alternative levels of willingness to pay for a QALY gain.
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Figure 19 reports the mean (with 95% CI) of the incremental net benefit (at £20,000 per QALY)
according to alternative assumptions, compared with the base case. These sensitivity analyses showed
that the results were robust to alternative scenarios.
Expert elicitation
Sixty-three individuals were sent a link to the elicitation questionnaire. Thirty-five experts submitted
completed questionnaires, of which 32 were classified as usable, 24 high confidence and six very high
confidence. Of the usable experts, 50% were medical doctors and 31% were clinical or research nurses,
59% had been in their current role for > 7 years and 91% had work that involved following up patients
in person after intensive care.
Table 24 summarises the elicitation responses across all usable experts. Overall, for patients receiving
usual care, the elicited average HRQoL scores were lower for patients who did not return their
questionnaire than the average from the observed data. For patients with missing HRQoL scores, the
elicited values were very slightly lower for those allocated to permissive hypotension than for those
allocated to usual care. There is a wide diversity in the elicited scores across experts, as indicated by
the SDs.
The results of the sensitivity analysis compared with the primary analysis and complete-case analysis are
summarised in Figures 20 and 21 for the HRQoL and the INMB, respectively, valuing QALY at £20,000 per
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FIGURE 18 Subgroup analysis for the cost-effectiveness primary outcome at 90 days. Vertical line indicates no difference
in net monetary benefits between comparator groups.
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FIGURE 19 Sensitivity analysis for the CEAs at 90 days. Vertical line indicates no difference in net monetary benefits
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FIGURE 20 Incremental net benefit estimates at 90 days post randomisation from sensitivity analyses exploring the
effects of MNAR assumptions vs. the primary and complete-case analyses. Note that for the complete-case analysis, the
posterior mean is almost zero and therefore beneath the blue line. Each shaded rectangular strip shows the full posterior
distribution. The darkness at a point is proportional to the probability density, such that the strip is darkest at the
maximum density and fades into the background at the minimum density. The posterior mean and 95% credible interval
are marked. For INMB, positive differences favour permissive hypotension.
TABLE 24 Summary of elicited EQ-5D-5L scores across all usable experts (n= 32)
Most likely patient EQ-5D-5La average scores (i.e. mode) Mean (SD)
Permissive hypotension group: did not return an EQ-5D-5L 68 (11)
Usual-care group: did not return an EQ-5D-5L 70 (11)
Differences in most likely patient EQ-5D-5L average scores
Usual-care group: did not return an EQ-5D-5L minus did return a EQ-5D-5L –7 (11)
Did not return an EQ-5D-5L: permissive hypotension minus usual care –1 (10)
a EQ-5D-5L scale is from –28 to 100, with lower scores indicating worse HRQoL.
Reproduced with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.
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and (2) the posterior distribution of the 90-day HRQoL difference (permissive hypotension – usual
care)/INMB. The full posterior distribution is shown as a density strip,67 where the darkness at a point is
proportional to the probability density. The results from the HRQoL sensitivity analysis are broadly similar
to the primary analysis in terms of point estimates, but with greater uncertainty about these. The extreme
individual priors provide greater differences: the probability that the mean HRQoL score is higher for
permissive hypotension is 99% and 37% for the ‘most enthusiastic’ expert and the ‘most sceptical’ expert,
respectively. For INMB, there is little difference between the results of any of the analyses.
Cost-effectiveness at 1 year
Resource use and costs up to 1 year
Table 25 presents resource use up to 1 year. The permissive hypotension group had a higher mean
number of days in critical care and general medical wards than the usual-care group between 90 days
and 1 year post randomisation. The average hospital length of stay prior to 1 year post randomisation
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FIGURE 21 Health-related quality-of-life treatment effect estimates at 90 days post randomisation from sensitivity
analyses exploring the effects of MNAR assumptions vs. the primary and complete-case analyses. Note that the posterior
mean, for the primary analysis (MAR), is almost zero and below the blue line. The entire posterior distribution is indicated
by each rectangular line (shaded). At each point, the shade is proportional to the probability density, meaning that a line
at the maximum density is darkest and fades as density decreases. There are markings for both the posterior mean and
the 95% credible interval. Positive HRQoL differences favour the permissive hypotension group. Reproduced with
permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.
TABLE 25 Resource use up to 1 year post randomisation
Resource use
Permissive hypotension
(n= 994), mean (SD)
Usual care (n= 1005),
mean (SD)
Total length of stay up to 90 days 19.81 (21.88) 19.30 (21.60)
Hospital length of stay from 90 days to 1 year: index admission
Days in critical care 0.15 (2.15) 0.03 (0.87)
General medical bed-days 1.59 (15.53) 1.07 (7.92)
Hospital length of stay from 90 days to 1 year: readmissions
Days in critical care 0.14 (1.36) 0.14 (1.72)
General medical bed-days 0.33 (3.32) 0.53 (7.08)
Total length of stay up to 1 year 22.02 (32.06) 21.07 (27.96)
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Resource use between 90 days and 1 year is summarised in Table 26. The usual-care group had a large
number of inpatient days (general medical), outpatient visits, contacts with GPs and nurses, and visits
to occupational therapists and physiotherapists. The permissive hypotension group had a larger number
of health visitor contacts. Other contacts related to community care were small and with no difference
between the groups.
Table 27 reports the total costs at 1 year across all the resource use items recorded. At 1 year, the
mean total cost per patient was £20,299 for the permissive hypotension group and £19,850 for the
usual-care group.
TABLE 26 Resource use from health services questionnaire between 90 days and 1 year post randomisation
Resource usea
Permissive hypotension
(n= 309), mean (SD)
Usual care (n= 303),
mean (SD)
Inpatient days (general medical) 5.94 (18.50) 7.14 (16.53)
Outpatient visits 4.19 (4.49) 4.50 (4.83)
GP contacts 3.35 (4.12) 3.40 (4.15)
Nurse contacts 4.36 (6.75) 4.50 (6.38)
Health visitor contacts 0.68 (3.42) 0.48 (1.96)
Occupational therapist contacts 0.51 (2.84) 0.88 (4.01)
Speech therapist contacts 0.15 (0.82) 0.08 (0.40)
Physiotherapist contacts 0.80 (1.99) 0.93 (2.61)
Psychiatrist contacts 0.02 (0.22) 0.14 (0.86)
Psychiatric nurse contacts 0.14 (0.80) 0.08 (0.61)
Psychologist contacts 0.02 (0.22) 0.06 (0.57)
Counsellor contacts 0.07 (0.58) 0.01 (0.08)
a Reported for patients who were alive and completed the health services questionnaire at 1 year post randomisation.






Total costs up to 90 daysa,b,c 18,455 (21,178) 18,003 (21,732)
90 days to 1 year hospital costs: index admission
Critical care 248 (3466) 46 (1334)
General medical ward 535 (5231) 361 (2669)
90 days to 1 year hospital costs: readmissiona
Critical care 218 (2284) 224 (3111)
General medical 113 (1118) 178 (2385)
Outpatient and community costsb,c 730 (2131) 1038 (3601)
Total costs up to 1 yeara,b,c 20,299 (25,501) 19,850 (24,676)
a 65 trial and CMP database.
b Health services questionnaire.
c Following multiple imputation to handle missing resource use data.
Note
All numbers are mean (SD) unless stated otherwise.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
Health-related quality of life at 1 year
The health status profiles reported from responses to the EQ-5D-5L at 1 year post randomisation are
summarised by randomised group in Table 28. At 1 year, the proportion who reported ‘no problems’
for each dimension of the EQ-5D-5L (except mobility) was similar in the randomised group. A higher
proportion of patients in the permissive hypotension group than in the usual-care group had reported
‘extreme problems’ for each dimension of EQ-5D-5L.
TABLE 28 Quality-of-life (EQ-5D-5L) health state profiles at 1 year post randomisation
EQ-5D-5L componenta
Permissive hypotension
(N= 309), n (%)
Usual care
(N= 303), n (%)
Mobility
No problems 79 (25.57) 62 (20.46)
Slight problems 51 (16.50) 63 (20.79)
Moderate problems 71 (22.98) 67 (22.11)
Severe problems 36 (11.65) 45 (14.85)
Extreme problems 17 (5.50) 7 (2.31)
Self-care
No problems 154 (49.84) 154 (50.83)
Slight problems 43 (13.92) 37 (12.21)
Moderate problems 31 (10.03) 32 (10.56)
Severe problems 11 (3.56) 16 (5.28)
Extreme problems 15 (4.85) 6 (1.98)
Usual activities
No problems 79 (25.57) 80 (26.40)
Slight problems 70 (22.65) 74 (24.42)
Moderate problems 54 (17.48) 50 (16.50)
Severe problems 28 (9.06) 27 (8.91)
Extreme problems 23 (7.44) 15 (4.95)
Pain/discomfort
No problems 79 (25.57) 74 (24.42)
Slight problems 81 (26.21) 73 (24.09)
Moderate problems 67 (21.68) 68 (22.44)
Severe problems 25 (8.09) 28 (9.24)
Extreme problems 3 (0.97) 4 (1.32)
Anxiety/depression
No problems 136 (44.01) 129 (42.57)
Slight problems 68 (22.01) 75 (24.75)
Moderate problems 35 (11.33) 38 (12.54)
Severe problems 10 (3.24) 2 (0.66)
Extreme problems 6 (1.94) 2 (0.66)
a Reported for patients who were alive and completed the health services questionnaire at 1 year post randomisation.
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Cost-effectiveness at 1 year
At 1 year, the average cost was higher in the permissive hypotension group and mean EQ-5D-5L
index scores were similar between groups (Table 29). The incremental life-years and QALYs were higher
in the permissive hypotension group, with the majority of points falling into those quadrants on the
cost-effectiveness plane indicating that permissive hypotension had higher mean QALYs (Figure 22).
The INMB for permissive hypotension compared with usual care was negative, but with a wide CI.
At £20,000 per QALY, the INMB was –£361 (95% CI −£2537 to £1815). The probability that permissive
hypotension is cost-effective is < 40% and 45% at the £20,000 and £30,000 per QALY threshold,
respectively (Figure 23).
The cost-effectiveness results at 1 year were similar across prespecified subgroups (Figure 24). The results
were similar for alternative scenarios considered in sensitivity analyses at 1 year (Figure 25).
TABLE 29 Cost-effectiveness up to 1 year
Outcome
Permissive hypotension
(n= 994) Usual care (n= 1005)
Incremental effect,
mean (95% CI)
Costs (£) 20,299 (25,501) 19,850 (24,676) 699 (–1466 to 2864)
EQ-5D-5L (survivors) 0.706 (0.264) 0.716 (0.245) –0.011 (–0.050 to 0.028)
Life-years 0.474 (0.465) 0.446 (0.464) 0.036 (–0.000 to 0.072)
QALYs 0.263 (0.324) 0.252 (0.322) 0.017 (–0.009 to 0.043)
INMB (£)a –361 (–2537 to 1815)
a The INMB is calculated in accordance with NICE methods guidance, by multiplying the mean QALY gain (or loss) by
£20,000 and subtracting from this the incremental cost.
Notes
The EQ-5D-5L, QALY, cost and INMB results are all reported after applying multiple imputation to handle missing data.
The incremental effects are reported after applying case-mix adjustment.
Reproduced with permission from Lamontagne et al.59 Copyright © 2020 American Medical Association.
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FIGURE 22 Uncertainty in the mean costs (£) and QALY differences and their distribution for intervention vs. usual care
(within 1 year post randomisation).
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FIGURE 24 Subgroup analysis for the cost-effectiveness outcome at 1 year. Vertical line indicates no difference in net
monetary benefits between comparator groups.
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FIGURE 25 Sensitivity analysis for the CEAs at 1 year. Reports the mean with 95% CI of the incremental net benefit
(at £20,000/QALY) according to alternative assumptions. The solid vertical line indicates no difference in net monetary
benefits between the treatment groups. Vertical line indicates no difference in net monetary benefits between
comparator groups. HSQ, health services questionnaire.
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Chapter 4 Discussion and conclusions
Principal findings
In patients aged ≥ 65 years who receive vasopressors for vasodilatory hypotension, permissive
hypotension did not significantly reduce mortality at 90 days. The absolute treatment effect on 90-day
mortality, based on the 95% CIs, was between a 6.8-percentage reduction and a 1.1-percentage
increase in mortality.
Patients in the permissive hypotension group received a lower exposure to vasopressors than those
in the usual-care group, in terms of both mean duration and total dose. For mean total dose of
vasopressors (noradrenaline equivalent), patients in the permissive hypotension group received
31.5 mg compared with 44.3 mg for patients in the usual-care group (difference −12.8 mg, 95% CI
−18.0 mg to −7.6 mg). Adherence to permissive hypotension was good. In occurrences where a
patients’ MAP was > 65 mmHg, vasopressors were not reduced or discontinued only 6% of the time.
There was no clinically important difference in fluid balance, urine output or the use of pure inotropes
between the groups.
Secondary outcomes and prespecified SAEs were similar in both groups. There was evidence of
heterogeneity of treatment effect within the chronic hypertension subgroup, with a lower mortality
rate observed in patients with chronic hypertension in the permissive hypotension than in patients
with chronic hypertension in the usual-care group. There was no evidence for heterogeneity of treatment
effect in other prespecified subgroups.
The economic evaluation found that permissive hypotension had similar costs and EQ-5D-5L index scores
to usual care; however, given higher incremental life-years and QALYs in the permissive hypotension
group, the INMB was positive at 90 days, but with high statistical uncertainty (£378, 95% CI −£1347 to
£2103). The probability that permissive hypotension is cost-effective is 70% at the £20,000 per QALY
threshold. The cost-effectiveness results were similar across prespecified subgroups for alternative
scenarios considered in sensitivity analyses, and over 1 year. The QALY gains associated with permissive
hypotension were positive, but relatively small, at both 90 days and 1 year. The incremental costs of
permissive hypotension relative to usual care was lower at 90 days, but at 1 year the intervention group
had higher costs. Therefore, although at 90 days the intervention was both more effective and cheaper,
at 1 year it was more effective but costlier. However, it should be highlighted that these mean cost-
effectiveness results at both 90 days and 1 year were surrounded by considerable statistical uncertainty.
The cost-effectiveness results were sensitive to relatively small QALY gains, leading to changes in the
probability of cost-effectiveness of permissive hypotension from 70% at 90 days to 40% at 1 year.
Our findings in context
Consistent with the hypothesis of the trial, the potential benefit of permissive hypotension appears
that it may increase with age when patients may become frailer and more vulnerable. This is in line
with the individual patient data meta-analysis11 of the SEPSISPAM (Sepsis and Mean Arterial Pressure)
trial13 and the OVATION (Optimal VAsopressor TItratiON) pilot trial,12 which suggest that older
patients may be at greater risk of harm from greater exposure to vasopressors.3
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It is a commonly held belief that patients with chronic hypertension benefit from higher MAPs, but our
trial appeared to show a greater benefit associated with permissive hypotension in patients with chronic
hypertension than in those without. However, this subgroup analysis (which was not adjusted for multiple
testing) should be interpreted with caution in the light of the non-significant primary analysis. In contrast
to the SEPSISPAM trial,13 in patients with chronic hypertension, we observed no clinically important
increase in the use of renal replacement therapy when using a lower MAP target. Although these results
suggest that it may be safe to tolerate lower blood pressure in patients with chronic hypertension,
further research is required to better understand the interaction between this chronic comorbidity
and vasopressors. In addition, patients who suffer from chronic hypertension are also at risk of other
comorbidities, potentially rendering them more vulnerable to vasopressor-induced adverse effects.
Strengths and limitations
Strengths
The 65 trial was a pragmatic trial, set in a real-world context. It was conducted in a large, representative
sample of 65 critical care units across the NHS. Using a simple intervention, designed to be implementable
if adopted across the NHS, and straightforward trial procedures, the trial was designed for efficiency of
delivery and generalisability of the results. This allowed central trial and local site set-up to be rapid,
with > 50 sites open to recruitment within 4 months of opening. Patient recruitment followed a similar
pattern, with the full sample of 2600 patients recruited in < 21 months, far exceeding the initial schedule
to recruit 1440 patients over an 18-month period. This was enabled through the ability of participating
sites to embed delivery of the trial into routine clinical practice, allowing randomisation to be carried
out 24 hours per day, 7 days per week, which compared favourably with previous trials. The following
elements contributed to this:
l The simplicity of the telephone randomisation process, with only minimal information at the point of
randomisation needed.
l The simplicity of the intervention and control groups, with the intervention being a straightforward
change to a threshold for delivery of vasopressors, which could be delivered by bedside nurses.
l Use of ‘research without prior consent’, which meant that the minority of staff who have undergone
training in taking informed consent did not need to be present prior to randomisation.
l Data collection being nested within routinely collected data, which meant that a parsimonious data
set could be defined for additional collection within the trial, focused on the key aspects of delivery
of the trial interventions and safety reporting.
l The ongoing development and experience of the UK Critical Care CRN, which has trained and
funded research nurses to be able to deliver trials, such as this, efficiently and effectively.
The decision to employ a usual-care, as opposed to a higher MAP target, control group meant that
we avoided the risk of potentially artificially increasing harm in the control group and ensured that the
control group was representative of the current standard of care in the NHS.68 Our design used the
results of previous studies to guide enrichment of the trial population, which involved enrolling older
patients who were considered to have a greater chance of benefiting from the intervention.
In contrast to the other trials in this area, the 65 trial integrated a rigorously designed and conducted
economic evaluation and included assessment of important patient-centred outcomes, such as HRQoL
and cognitive decline, among survivors. These important outcomes are often valued by patients above
90-day mortality.69,70
Both the protocol22 and statistical analysis plan47 were submitted for publication during the
recruitment period to ensure transparency, and all analyses were conducted following the analysis
plan. Sensitivity analyses were also conducted, which comprised different approaches to handling
missing data, including MAR and MNAR.
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The study has measured quality of life with the EQ-5D-5L. This version of the instrument was
anticipated to be sensitive to differences in health status between the treatment groups. EQ-5D-5L
descriptive data at 90 days and 1 year were valued using a published EQ-5D-5L value set for England,
as set out in the original proposal and statistical and health economic analysis plan. Over the time
that the study was conducted, the EQ-5D-5L value set for England was subject to criticism and NICE
have recommended using a crosswalk value sets (three to five level) via a ‘mapping algorithm’,63 which
provides an interim means of scoring EQ-5D-5L, while a new five-level value set is developed. As both
the currently available five-level value set (considered in our base case) and the crosswalk approach
(considered in our sensitivity analysis) are subject to concerns, we considered that using both approaches
was appropriate. In the 65 trial, there was no difference in patients described health status according to
the EuroQol-5 Dimensions descriptive system and therefore the results were insensitive to the choice
of approach to health state valuation.
Limitations
Owing to the nature of the intervention, it was not blinded. However, the use of outcomes collected
through routine sources that are not subject to observer bias, including the objective primary outcome,
would have minimised any potential bias. When compared with the sample size assumptions, there
were two small differences:
1. A higher mortality rate was observed in the usual-care group. This may have been due to not being
able to take into account the full eligibility criteria in routinely collected data. For example, clinical
audit data would not have the granularity of data or be able to capture a subjective decision, such
as whether or not the clinical team expected vasopressors to continue for an additional 6 hours or
more. Therefore, a proportion of the less sick patients, who had lower vasopressor requirements,
were probably excluded from the trial, but included within the sample size assumptions.
2. The rate of non-consent was slightly higher than anticipated. This was the first trial of this size
carried out in this population using a ‘research without prior consent’ model in the UK. These
results will be important in informing future trial design and planning in the future.
When describing exposure to vasopressors, it was not possible to convert doses of metaraminol into
a noradrenaline-equivalent dose. To our knowledge, no formula for such dose conversion exists,
potentially because of there being no relationship between doses of metaraminol and noradrenaline.71
As a pragmatic trial that uses an efficient design and parsimonious data set, no mechanistic data were
collected, which meant that the attributable mortality could not be adjudicated. In addition, we did not
carry out an integrated process evaluation, which could have provided additional contextual factors
around clinician and team behaviour.
Implications for health care/practice
The CI for the absolute risk difference, as well as the adjusted analysis, indicates that minimising exposure
to vasopressors in older patients with vasodilatory hypotension is unlikely to be harmful and may be
beneficial for patients. This may be because critical care patients are particularly susceptible to iatrogenic
complications and ‘less may be more’.72,73 Usual care, which allowed expert clinicians to individualise
vasopressors in view of an array of parameters (e.g. patient characteristics and markers of tissue perfusion),
did not outperform use of a single parameter, the MAP, to minimise exposure to vasopressors.
In addition, the longer-term patient-centred outcomes, such as quality of life and cognitive decline,
supported the notion that permissive hypotension is safe. The fact that potential differences in survival
were observed largely only after critical care unit discharge suggests that the risks posed by greater
exposure to vasopressors therapy may not be immediate, which may explain why they are under-reported.
Ongoing mechanistic studies may shed further light on this.
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Although adherence to permissive hypotension was good, there were areas for improvements that our
trial should cast light on. There were two main reasons for not reducing or discontinuing vasopressors
when the MAP was above the target range. First, a lack of trial awareness (n = 54) meant that some
staff (often not full-time critical care unit staff) did not realise that they were supposed to be actively
titrating vasopressors to a lower MAP target. Second, there was a focus on other clinical priorities
(n = 42), which led to vasopressors being left at the same dose rate while the clinical staff completed
other tasks. This suggests that, even though less may be more beneficial, a more active involvement of
clinical staff to reduce exposure to vasopressors is required. Our trial also addresses the concerns over
the perceived need for higher MAP targets for patients with chronic hypertension and with low urine
output. Use of these surrogate outcomes to guide vasopressors does not necessarily lead to longer-term
improvements in patient-centred outcomes.
There were positive implications shown for the research infrastructure within the NHS. As reported
above, there was overwhelming interest in the trial, with > 100 sites expressing interest in participating.
Within the 65 participating sites, even though there was a short time frame to recruit patients (up to
6 hours from becoming eligible), patients were randomised early and recruitment rates exceeded the
pre-trial estimates. This was because of the ability of sites to embed the trial procedures within their
routine clinical practice, providing a template for future studies in this complex setting to use more
efficient and embedded procedures.
Summaries of key research recommendations
Recommendation 1: individual patient data meta-analysis
Our trial was the next step in the evaluation of blood pressure targets in critical care. The opportunity
to pool the data from the previous two RCTs (SEPSISPAM13 and OVATION12) with our data will give
additional power for evaluating this group of patients and assess intervention effects in potentially
important subgroups. As this will include data across the UK, France and Canada, it will enhance
generalisability and improve knowledge on this important area for critical care worldwide.
Recommendation 2: evaluate heterogeneity of treatment effect
In conventional subgroup analyses alongside RCTs, a number of one-at-a-time subgroups and thresholds
defining each subgroup are prespecified. Significance testing of subgroup interactions is the main approach
for the evaluation of subgroup effects. This may fail to fully capture variation in complex baseline risk
factors and their consequent moderation of treatment effects. RCTs are also generally underpowered to
detect subgroup effects. In this context, machine learning methods that have been developed to identify
subgroups with different treatment effects, allowing the estimation of individual average treatment
effects, without relying on any a priori modelling assumptions, would be useful as an alternative approach
to detect and estimate true subgroup effects.
Recommendation 3: further research on the conduct, including use of research without
prior consent model
Further research should study the efficient conduct of our trial, which used simple, straightforward
procedures and a research without prior consent model, to further understand the implications of
these procedures with the hope of producing guidance for future studies in the critical care setting.
One of the key aspects is that our trial is one of the largest studies in the adult critical care setting in
the UK to employ a research without prior consent model. It is therefore vital to use the extensive
data collected on the consent process to look into patient and family member preferences and
agreement, and the mechanism of consent in the UK, for example timing of consent.
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Appendix 1 The 65 trial investigators
Lead investigators
Paul R Mouncey, Intensive Care National Audit & Research Centre, London, UK
Alvin Richards-Belle, Intensive Care National Audit & Research Centre, London, UK
Karen Thomas, Intensive Care National Audit & Research Centre, London, UK
David A Harrison, Intensive Care National Audit & Research Centre, London, UK
M Zia Sadique, London School of Hygiene & Tropical Medicine, London, UK
Richard D Grieve, London School of Hygiene & Tropical Medicine, London, UK
Julie Camsooksai, Poole Hospital NHS Foundation Trust, Poole, UK
Robert Darnell, Intensive Care National Audit & Research Centre, London, UK
Anthony C Gordon, Imperial College London, London, UK, and Imperial College Healthcare NHS Trust,
St Mary’s Hospital, London, UK
Doreen Henry (patient representative), UK
Nicholas Hudson, Intensive Care National Audit & Research Centre, London, UK
Alexina J Mason, Imperial College London, London, UK
Michelle Saull, Intensive Care National Audit & Research Centre, London, UK
Chris Whitman (patient representative), UK
J Duncan Young, University of Oxford, Oxford, UK
François Lamontagne, Université de Sherbrooke, Sherbrooke, QC, Canada
Kathryn M Rowan, Intensive Care National Audit & Research Centre, London, UK
Site investigators
Petra Polgarova, Addenbrookes Hospital, Cambridge, UK
Peter Featherstone, Addenbrookes Hospital, Cambridge, UK
Sofia Teixeira, Addenbrookes Hospital, Cambridge, UK
Colette Jones-Criddle, Aintree University Hospital, Liverpool, UK
Ben Morton, Aintree University Hospital, Liverpool, UK
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Ian Turner-Bone, Aintree University Hospital, Liverpool, UK
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McDonald Mupudzi, Basingstoke and North Hampshire Hospital, Basingstoke, UK
Jason Cuppitt, Blackpool Victoria Hospital, Blackpool, UK
Emma Stoddard, Blackpool Victoria Hospital, Blackpool, UK
Gemma Brown, Blackpool Victoria Hospital, Blackpool, UK
Jazmine McCooey, Blackpool Victoria Hospital, Blackpool, UK
Lisa Grimmer, Bristol Royal Infirmary, Bristol, UK
Jeremy Bewley, Bristol Royal Infirmary, Bristol, UK
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Chloe Searles, Bristol Royal Infirmary, Bristol, UK
Rebecca Keskeys, Broomfield Hospital, Chelmsford, UK
Jayachandran Radhakrishnan, Broomfield Hospital, Chelmsford, UK
Fiona McNeela, Broomfield Hospital, Chelmsford, UK
Sue Smolen, Broomfield Hospital, Chelmsford, UK
Laura Curran, Charing Cross Hospital, London, UK
David Antcliffe, Charing Cross Hospital, London, UK
Roceld Rojo, Charing Cross Hospital, London, UK
Kim Zantua, Charing Cross Hospital, London, UK
Helen Robertson, Countess of Chester Hospital, Chester, UK
Lyndsay Cheater, Countess of Chester Hospital, Chester, UK
Maria Faulkner, Countess of Chester Hospital, Chester, UK
Laura Parry, Countess of Chester Hospital, Chester, UK
Phillipa Wakefield, Darent Valley Hospital, Dartford, UK
Zakaulla Belagodu, Darent Valley Hospital, Dartford, UK
Danielle Vosper, Darent Valley Hospital, Dartford, UK
Carmel Stuart, Darent Valley Hospital, Dartford, UK
Binu Ravindran, Darent Valley Hospital, Dartford, UK
Amanda Cowton, Darlington Memorial Hospital, Darlington, UK
James Limb, Darlington Memorial Hospital, Darlington, UK
Julie O’Brien, Darlington Memorial Hospital, Darlington, UK
Rosalyn Squires, Derriford Hospital, Plymouth, UK
Sam Waddy, Derriford Hospital, Plymouth, UK
Esme Elloway, Derriford Hospital, Plymouth, UK
Helen McMillan Derriford Hospital, Plymouth, UK
Sarah Williams, Dorset County Hospital, Dorchester, UK
Andrew Ball, Dorset County Hospital, Dorchester, UK
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Patricia Williams, Dorset County Hospital, Dorchester, UK
Sharon Hiscox, Dorset County Hospital, Dorchester, UK
Sarah Horton, Dorset County Hospital, Dorchester, UK
Ulla Chappell, Glangwili General Hospital, Carmarthen, UK
Igor Otahal, Glangwili General Hospital, Carmarthen, UK
Peter Havalda, Glangwili General Hospital, Carmarthen, UK
Samantha Coetzee, Glangwili General Hospital, Carmarthen, UK
Kelly Matthews, Gloucestershire Royal Hospital, Gloucester, UK
Andrew Foo, Gloucestershire Royal Hospital, Gloucester, UK
Izzy King, Gloucestershire Royal Hospital, Gloucester, UK
Kirsty Manns, Gloucestershire Royal Hospital, Gloucester, UK
Sonia Sousa Arias, Hammersmith Hospital, London, UK
Stephen Brett, Hammersmith Hospital, London, UK
Leilani Cabreros, Hammersmith Hospital, London, UK
Rhoda Rosal, Hammersmith Hospital, London, UK
Stephanie Bell, Ipswich Hospital, Ipswich, UK
Kate Turner, Ipswich Hospital, Ipswich, UK
Vanessa Rivers, Ipswich Hospital, Ipswich, UK
Susan Brixey, Ipswich Hospital, Ipswich, UK
Lindsay Garcia, James Cook University Hospital, Middlesbrough, UK
Judith Wright, James Cook University Hospital, Middlesbrough, UK
Keith Hugill, James Cook University Hospital, Middlesbrough, UK
Susan Mortimer, James Cook University Hospital, Middlesbrough, UK
Nicola Cree, James Cook University Hospital, Middlesbrough, UK
Fiona Bartley, King’s College Hospital, London, UK
Philip Hopkins, King’s College Hospital, London, UK
Su Jeffreys, King’s College Hospital, London, UK
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Harriet Noble, King’s College Hospital, London, UK
Clare Finney, King’s College Hospital, London, UK
Louise Houslip, Leicester Royal Infirmary, Leicester, UK
Neil Flint, Leicester Royal Infirmary, Leicester, UK
Dawn Hales, Leicester Royal Infirmary, Leicester, UK
Prematie Andreou, Leicester Royal Infirmary, Leicester, UK
Iain McLaren, Leicester Royal Infirmary, Leicester, UK
Carina Cruz, Lister Hospital, Stevenage, UK
Sunil Jamadarkhana, Lister Hospital, Stevenage, UK
Naomi Brice, Lister Hospital, Stevenage, UK
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Richard Clark, Manchester Royal Infirmary, Manchester, UK
Jonathan Bannard-Smith, Manchester Royal Infirmary, Manchester, UK
Emma Connaughton, Manchester Royal Infirmary, Manchester, UK
Abigail Williams, Manchester Royal Infirmary, Manchester, UK
Amanda Cameron, Medway Maritime Hospital, Gillingham, UK
Rahuldeb Sarkar, Medway Maritime Hospital, Gillingham, UK
Vongayi Ogbeide, Medway Maritime Hospital, Gillingham, UK
Mary Everett, Medway Maritime Hospital, Gillingham, UK
Ceri Battle, Morriston Hospital, Swansea, UK
Milercy Oliveros, Morriston Hospital, Swansea, UK
Tracy Owen, Morriston Hospital, Swansea, UK
Sharon Storton, Morriston Hospital, Swansea, UK
Patricia Doble, Musgrove Park Hospital, Taunton, UK
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Georgina Randell, Norfolk and Norwich University Hospital, Norwich, UK
Steve Hutchinson, Norfolk and Norwich University Hospital, Norwich, UK
Deirdre Fottrell-Gould, Norfolk and Norwich University Hospital, Norwich, UK
Lisa Hudig, Norfolk and Norwich University Hospital, Norwich, UK
Tracey Shanley, North Devon District Hospital, Barnstaple, UK
Guy Rousseau, North Devon District Hospital, Barnstaple, UK
Max Coupe King, North Devon District Hospital, Barnstaple, UK
Nicolas Stafford, North Devon District Hospital, Barnstaple, UK
Joy Grewcock, Northampton General Hospital, Northampton, UK
Jonathan Wilkinson, Northampton General Hospital, Northampton, UK
Kathryn Hall, Northampton General Hospital, Northampton, UK
Lorraine Campey, Northampton General Hospital, Northampton, UK
Joanne Pons, Northern General Hospital, Sheffield, UK
Gary Mills, Northern General Hospital, Sheffield, UK
Sarah Bird, Northern General Hospital, Sheffield, UK
Joshua Cooper, Northern General Hospital, Sheffield, UK
Alan Pope, Peterborough City Hospital, Peterborough, UK
Matthew Davies, Peterborough City Hospital, Peterborough, UK
Coralie Carle, Peterborough City Hospital, Peterborough, UK
Nicola Butterworth-Cowin, Peterborough City Hospital, Peterborough, UK
Loran Davies, Pinderfields Hospital, Wakefield, UK
Alastair Rose, Pinderfields Hospital, Wakefield, UK
Sarah Buckley, Pinderfields Hospital, Wakefield, UK
Lucy Brooks, Pinderfields Hospital, Wakefield, UK
Sarah Smith, Pinderfields Hospital, Wakefield, UK
Julie Camsooksai, Poole Hospital, Poole, UK
Henrik Reschreiter, Poole Hospital, Poole, UK
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Sarah Patch, Poole Hospital, Poole, UK
Sarah Jenkins, Poole Hospital, Poole, UK
Olivia Rowe, Princess Royal University Hospital, Farnborough, UK
Tom Williams, Princess Royal University Hospital, Farnborough, UK
Emma Clarey, Princess Royal University Hospital, Farnborough, UK
Jane Wilson, Princess Royal University Hospital, Farnborough, UK
Jenny Ritzema, Queen Elizabeth Hospital, Gateshead, UK
Vanessa Linnett, Queen Elizabeth Hospital, Gateshead, UK
Amanda Sanderson, Queen Elizabeth Hospital, Gateshead, UK
Steve Rose, Queen Alexandra Hospital, Portsmouth, UK
David Pogson, Queen Alexandra Hospital, Portsmouth, UK
Zoe Daly, Queen Alexandra Hospital, Portsmouth, UK
Aimi Collins, Queen Alexandra Hospital, Portsmouth, UK
Amy Collins, Queen Elizabeth Hospital, London, UK
Ashraf Roshdy, Queen Elizabeth Hospital, London, UK
Ahmed Zaki, Queen Elizabeth Hospital, London, UK
Estefania Treus, Queen Elizabeth Hospital, London, UK
Yvonna Marasigan, Queen Elizabeth Hospital, London, UK
Lucy Ryan, Queens Medical Centre, Nottingham, UK
Daniel Harvey, Queens Medical Centre, Nottingham, UK
Megan Meredith, Queens Medical Centre, Nottingham, UK
Louise Hughes, Queens Medical Centre, Nottingham, UK
Nicola Jacques, Royal Berkshire Hospital, Reading, UK
Andrew Walden, Royal Berkshire Hospital, Reading, UK
Parminder Bhuie, Royal Berkshire Hospital, Reading, UK
Aoife Dowling, Royal Berkshire Hospital, Reading, UK
Sarah Bean, Royal Cornwall Hospital, Truro, UK
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